~~United~~UNITED ~~States~~STATES SECURITIES ~~Securities~~AND ~~and~~EXCHANGE ~~Exchange Commission~~COMMISSION

Washington, D.C. 20549

~~Form 10-K~~_________________

FORM 10-K

_________________

(Mark One)

☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~For~~ For the fiscal year ending : June 30, ~~2022~~ 2023.

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~For~~ For the transition period from ~~__________ to __________.~~

Commission ~~file~~File ~~number~~Number: 333-248059

SYBLEU INC.
(Name of small business issuer in its charter)
Wyoming		85-1412307
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
4700 Spring Street, Suite 304, La Mesa, California, 91942
(Address of Principal executive offices)

_____________________

~~Issuer’s telephone~~SYBLEU ~~number: (619) 227-9192~~ INC.

~~Securities~~(Exact ~~registered~~name ~~under~~of ~~Section~~registrant ~~12(b)~~as ofspecified ~~the~~in ~~“Exchange~~its ~~Act”: None~~charter)

_____________________

Wyoming		85-1412307
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1034 Throggs Neck Expressway Bronx, NY		10465
(Address of principal executive offices)		(Zip Code)

(800) 807-4631

(Issuers’s telephone number)

N/A

(Former name or former address and former fiscal year, if changed since last report)

_________________

Securities registered pursuant to Section 12(b) of the “Exchange Act”: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark ifwhether ~~disclosure~~the ofregistrant ~~delinquent~~has ~~filers~~submitted ~~pursuant~~electronically every Interactive Data File required to ~~Item~~be submitted pursuant to Rule 405 of Regulation S-KT (§ ~~229~~232.405 of this chapter) isduring ~~not contained herein, and will not be contained, to~~ the ~~best~~preceding of12 ~~registrant’s~~months ~~knowledge,~~(or infor ~~definitive~~such ~~proxy~~shorter orperiod ~~information~~that ~~statements~~the ~~incorporated~~registrant bywas ~~reference~~required ~~in Part III of this Form 10-K or any amendment~~ to ~~this~~submit ~~Form~~such ~~10-K~~files).

~~Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or smaller reporting company.~~Yes ☒ No ☐

~~Large~~Indicate by check mark whether the registrant is a large accelerated filer, ☐an ~~Accelerated~~accelerated filer, ☐a ~~Non~~non-accelerated filer, ☐or ~~Smaller~~a smaller reporting company. ~~Company~~See ☒the ~~Emerging~~definitions ~~Growth~~of ~~Company~~“large ☐accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☐ No ☒

~~Indicate~~APPLICABLE byONLY ~~check~~TO ~~mark~~CORPORATE whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).ISSUERS

~~Yes~~State the aggregate market value of the voting ~~☐ No~~and ☒ non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: N/A0

~~State the~~As ~~aggregate market value~~ of ~~the voting and non-voting common equity held by non-affiliates computed by reference to the price at which~~ ~~the~~July ~~common equity was last sold~~30, or2023 ~~the~~SYBLEU ~~average~~INC. ~~bid and asked price of such common equity~~had 10, ~~as of the last business day of the registrant’s~~613,492 common ~~most~~shares ~~recently completed second fiscal quarter: N/A 0~~outstanding.

As of July 16, 2022 SYBLEU INC had : 10,418,000 common shares outstanding.

In this annual report, the terms “~~SYBLEU~~Sybleu ~~INC~~Inc... ”, “~~SYBLEU~~Sybleu”, “Company”, “we”, or “our”, unless the context otherwise requires, mean ~~SYBLEU~~Sybleu ~~INC~~Inc.., a Wyoming corporation..

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This annual report on Form 10-K and other reports that we file with the SEC contain statements that are considered forward-looking statements. Forward-looking statements give the Company’s current expectations, plans, objectives, assumptions or forecasts of future events. All statements other than statements of current or historical fact contained in this annual report, including statements regarding the Company’s future financial position, business strategy, budgets, projected costs and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plans,” “potential,” “projects,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend,” and similar expressions. These statements are based on the Company’s current plans and are subject to risks and uncertainties, and as such the Company’s actual future activities and results of operations may be materially different from those set forth in the forward looking statements. Any or all of the forward-looking statements in this annual report may turn out to be inaccurate and as such, you should not place undue reliance on these forward-looking statements. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. The forward-looking statements can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and assumptions due to a number of factors, including:

•

dependence on key personnel;

•

competitive factors;

•

degree of success of research and development programs

•

the operation of our business; and

•

general economic conditions

These forward-looking statements speak only as of the date on which they are made, and except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements contained in this annual report.

PART I

Item 1. Business

We were incorporated June 12, 2020 under the laws of the State of Wyoming. We ~~are~~intend ato ~~majority~~develop ~~owned~~therapies ~~subsidiary~~for ofhuman ~~Cell~~and ~~Source~~animal ~~Research~~health, ~~Inc.,~~medical adevices, ~~Delaware~~and ~~corporation~~clinical diagnostics. WeThe ~~intend~~Company intends to engage ~~primarily~~ in the acquisition, licensing and development of ~~regenerative~~ medical and veterinary applications up to the point of successful completion of Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials.

2We are currently focused on acquiring intellectual property and forging strategic partnerships to advance technologies to market.

OnAcquired ~~July~~Intellectual ~~14,~~Property 2020 we were assigned all right, title, and interest to intellectual property related to methods, devices, and techniques useful for enhancing function of a cellular graft through photoceutical ( the use of low level light therapeutics) manipulation . These rights were assigned to us by the Company’s Chief Executive Officer and Entest Biomedical, Inc., a California corporation controlled by the Company’s Chief Executive Officer.

~~This~~On July 14, 2020 we were assigned all right, title, and interest to intellectual property ~~forms~~related ~~the~~to ~~basis~~methods, devices, and techniques useful for enhancing function of a cellular graft through photoceutical ( the ~~Company’s~~use ~~first~~of ~~medical~~low ~~application~~level ~~under~~light ~~development~~therapeutics) manipulation ( “Cell Transplant IP”).

~~Principal~~On ~~Products~~December 2, 2020 Sybleu Inc.. (the “Company”) was assigned all right, title, and ~~Services~~interest to intellectual property related to intratumoral administration of a combination of a chemotherapeutic agent and an immunomodulatory agent for cancer therapy ( “Cancer Therapy IP”).

~~The~~On ~~Cell~~June ~~Transplant~~30, IP2023 ~~comprises~~Sybleu ~~methods,~~Inc. ~~devices,~~(the ~~and~~“Company”) ~~techniques~~entered ~~useful~~into ~~for~~an ~~enhancing~~agreement ~~function~~(“Agreement”) ofwhereby athe ~~cellular~~Company ~~graft~~purchased from ~~through~~Zander ~~photoceutical manipulation~~Biologics, Inc. (“Zander”) a 50% interest in

~~The~~(a)the ~~Cell~~invention ~~Transplant~~disclosed IPin ~~encompasses~~US Patent US11377442B2 (Small molecule agonists and antagonists of NR2F6 activity), all patent rights to the ~~following:~~invention described in US Patent US11377442B2 as well as all trade secrets, trademarks and associated good will to the invention described in US Patent US11377442B2 and

(ab) the ~~Methods~~invention ofdisclosed ~~increasing~~in ~~efficacy~~US Patent US US10472351B2 (Small molecule agonists and antagonists of aNR2F6 ~~cell~~activity ~~for~~in ~~use~~animals), all patent rights to the invention described in ~~transplantation~~US byPatent ~~pretreatment~~US10472351B2 ofas ~~said~~well ~~cell~~as ~~prior~~all trade secrets, trademarks and associated good will to ~~transplantation~~the invention ~~with~~described ain ~~laser~~US ~~irradiation~~Patent US10472351B2.

(b“IP Rights”) ~~Methods of augmenting efficacy of a cellular graft subsequent to transplantation by treating the area in which said graft will be transplanted with laser irradiation~~.

~~(c)~~The IP ~~Methods~~rights ofare ~~decreasing~~to ~~neutropenic~~patent ~~(Neutropenia~~protected issmall amolecule ~~condition~~compounds ~~that~~which ~~results~~compounds ~~when the body does not~~ have ~~enough~~been ~~neutrophils,~~found ~~an important white blood cell that fights infections) time in a patient subsequent~~ to amodulate ~~hematopoietic~~the ~~cell~~immune transplantation consisting of: a) extraction of a hematopoietic ( blood cell forming) stem cell source; b) administration of low level laser irradiation to said hematopoietic stem cell source at a sufficient energy and wavelength to increase hematopoietic reconstitution activity of said hematopoietic stem cell source; c) administration of treated cells; and/or d) providing low level laser irradiation to long bones of said patient at a sufficient energy and wavelength to increase hematopoietic stem cell engraftmentsystem.

~~(d)~~Pursuant to ~~Methods~~the ofAgreement ~~treating~~the aCompany ~~cytopenia~~issued (to ~~low~~Zander ~~blood cell count) consisting of :~~ a) ~~extraction~~promissory ofnote ain ~~hematopoietic~~the ~~stem~~principal ~~cell~~amount ~~source; b) administration~~ of ~~low~~$300,000 ~~level~~bearing ~~laser~~simple ~~irradiation~~interest ~~to said hematopoietic stem cell source~~ at a10% ~~sufficient~~per annum ~~energy~~as ~~and~~consideration ~~wavelength~~for to50% ~~increase~~interest ~~hematopoietic~~in ~~reconstitution~~the ~~activity~~IP ofrights. ~~said~~The ~~hematopoietic~~promissory ~~stem~~note ~~cell source; c) administration of treated cells;~~ and~~/or~~ d)all ~~providing~~accrued ~~low~~interest ~~level~~are ~~laser~~due ~~irradiation to long bones of said patient at a sufficient energy~~ and ~~wavelength~~payable toJune ~~increase~~30, ~~hematopoietic stem cell engraftment~~2025.

In ~~The~~the ~~Cell~~event ~~Transplant~~that IPon isor ~~intended~~prior to beJuly ~~utilized~~31, ~~primarily~~2023 inZander ~~connection~~causes ~~with~~to ~~Hematopoietic~~be ~~stem~~filed ~~cell~~with ~~transplantation.~~the ~~Hematopoietic stem~~United ~~cell~~States ~~transplantation~~Patent ~~involves~~and ~~the~~Trademark ~~intravenous~~Office ~~infusion~~any ofand ~~autologous~~all documentation orwhich ~~allogeneic~~may ~~stem~~be ~~cells~~required ~~collected~~in ~~from~~order ~~bone~~to ~~marrow,~~record ~~peripheral blood,~~the ortransfer ~~umbilical~~of ~~cord~~the ~~blood~~50% Interest to ~~reestablish~~the ~~hematopoietic~~Company ~~function~~Zander inshall ~~patients~~receive ~~whose~~additional consideration ~~bone~~consisting ~~marrow~~of or1,000,000 ~~immune~~common ~~system~~shares isof ~~damaged~~the ~~or defective~~Company.

In hematopoietic cell transplantation, the patient is given very high doses of chemotherapy or radiation therapy, intended to kill resistant cancer cells. This also destroys the normal cells in the bone marrow, including stem cells. After the treatment, the patient is given a supply of transplanted stem cells. The transplanted cells then reestablish the blood cell production process in the bone marrow.

In situations of hematopoietic stem cell transplantation recipient bone marrow is usually ablated in order to provide “space” for the donor bone marrow cells. Additionally, when treatment of hematological malignancies is being performed, the recipient cells need to be eradicated in order to cure the neoplasia (uncontrolled growth of cells). This process of hematological ablation (removal of tissue) involves exposing the patient to a period of immune deficiency. During this period multiple infections occur, which in a non- insignificant number of cases are lethal. Accordingly, it is of great interest accelerate the process of donor bone marrow engraftment and hematopoietic reconstitution.

The Cell Transplant IP provides means of “preactivating” a cellular graft before implantation. Said “preactivation” refers to induction of biochemical processes within the graft so as to allow for: a) increased viability; b) augmented function; c) accelerated integration with the tissue in which implantation of cellular graft has occurred. In the context of hematopoietic stem cell the IP provides methods of augmenting ability of transplanted stem cells to enter and incorporate into the bone marrow niche, to self renew and proliferate once established in said niche, and to generate blood cells. Preactivation is accomplished through the use of low level laser irradiation before infusion. Administration of low level laser irradiation to long bones may also be used for acceleration of stem cell reconstitution after administration. The above statements regarding preactivation of a cellular graft and any descriptions within this document of the benefits of preactivating a cellular graft with the Cell Transplant IP before implantation are based solely on management’s belief.

The ~~preactivation~~Company ofand ~~stem~~Zander ~~cells~~(The ~~before~~“Parties”) ~~administration~~agree into ~~myeloablated~~jointly ~~patients~~develop ~~may~~and becommercialize ~~performed~~the ~~with~~IP aRights ~~medical~~for ~~device~~veterinary ~~comprised~~use ofupon ~~a closed~~mutually ~~system~~acceptable terms and conditions. ~~Myeloablation~~Each isParty ashall ~~severe~~be ~~form~~entitled to 50% of ~~myelosuppression;~~any aand ~~condition~~all inrevenues ~~which~~derived ~~bone~~from ~~marrow~~development ~~activity~~and iscommercialization .Each ~~decreased,~~Party ~~resulting~~shall inbe ~~fewer red~~responsible ~~blood~~for ~~cells,~~50% ~~white~~of ~~blood~~all ~~cells,~~any and ~~platelets~~all expenses incurred in connection with development and commercialization.

~~Said~~Neither ~~device~~Party ~~contains~~shall antransfer ~~inlet~~right, ~~that~~title ~~connects~~and interest in aand ~~closed manner~~ to aincluding, ~~cryobag~~but ~~using~~not ~~connection~~limited ~~systems~~to, ~~available in~~ the ~~art~~copyrights, ~~such~~trade assecrets, ~~Leuer~~trademarks ~~Lock~~and (aassociated ~~device~~good ~~utilizing~~will ~~leak~~and ~~free~~patent ~~fittings~~rights ~~which~~to ~~are~~the ~~securely~~IP ~~joined~~Rights byin ~~means~~whole ofor ain ~~tabbed~~part ~~hub~~without on the ~~female~~written ~~fitting~~consent ~~which~~of ~~screws into threads in a sleeve on~~ the ~~male~~other ~~fitting)~~Party. ~~Access~~Neither toParty shall ~~cells~~grant ~~pre~~any ~~and~~rights ~~post-irradiation~~or islicense ~~provided~~to ~~using~~the ~~valves~~IP ~~that~~Rights ~~allow~~to ~~for~~any ~~sample~~entity ~~collection. This~~without isthe anwritten ~~important~~consent ~~part~~ of ~~quality control for~~ the ~~cells.~~other ~~Classical parameters of interest include cell viability and morphology~~Party.

~~Said~~Licenses ~~device~~Granted ~~further~~by ~~consists of a surface area of sufficient size so that cells from~~ the cryobag or other sterile source can be exposed to irradiation in a uniform or semi-uniform manner. Said device may further possess a rocking mechanism to ensure cell dispersion. Under the surface area a low level laser is provided that administers the desired frequency and intensity of laser irradiation to said cellsCompany

~~The~~On ~~Company~~February ~~has~~24, ~~yet~~2021 toSybleu ~~either~~Inc. ~~develop~~( ~~or in license~~ the ~~closed~~“Company”) ~~system~~and ~~described~~Oncology ~~above~~Pharma, Inc. ~~Such~~( a“Licensee”) ~~closed~~entered ~~system~~into ~~would~~an ~~likely be regulated as~~agreement awhereby ~~Medical~~the ~~Device.~~Company ~~The~~granted ~~FDA regulates~~ the ~~development,~~Licensee ~~clinical~~an ~~testing,~~exclusive ~~manufacturing,~~worldwide ~~labeling,~~right ~~storage,~~and ~~record-keeping,~~license ~~promotion,~~for ~~marketing, sales,~~the ~~distribution~~development and ~~post-market~~commercialization ~~support and reporting~~ of ~~medical devices in the United States to ensure that medical products distributed~~certain ~~domestically~~intellectual ~~are~~property ~~safe~~controlled ~~and~~by ~~effective~~the ~~for~~Company ~~their intended uses~~(“Agreement”).

Unless an exemption applies, before a medical device can be commercially distributed in the United States and, depending on the classification of the device, either prior 510(k) clearance, 510(k) de-novo clearance or premarket approval (PMA), must be obtained from the FDA. A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device. A 51(k) de novo establishes new “device type” along with classification).

The FDA classifies medical devices into one of three classes based on the degree of risk associated with each medical device and the extent of regulatory controls needed to ensure the device’s safety and effectiveness:

• Class I devices, which are low risk and subject to only general controls (e.g., registration and listing, medical device labeling compliance, Medical Device Reporting Regulations, Quality System Regulations, and prohibitions against adulteration and misbranding) and, in some cases, to the 510(k) premarket clearance requirements;

• Class II devices, which are moderate risk and generally require 510(k) or 510(k) de-novo premarket clearance before they may be commercially marketed in the United States as well as general controls and potentially special controls like performance standards or specific labeling requirements; and

• Class III devices, which are devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device. Class III devices generally require the submission and approval of a PMA supported by clinical trial data.

No assurance can be given that any device which may be utilized to function as part of the “closed system” described would be granted approval by the FDA to be commercially distributed. The Company has yet to determine whether it will attempt to develop such a “closed system” internally or attempt to in license such a system. Such determination is intended to occur upon consultation with a Contract Research Organization or other qualified expert. The Company has yet to retain a Contract Research Organization or consult with an expert qualified to advise the Company regarding medical devices. The Company has not conducted any preclinical studies to provide evidence of the Company’s belief that the Cell Transplant IP provides a means to preactivate a cellular graft before implantation and that such preactivation would provide the benefits described above.

In arriving at the belief that the Cell Transplant IP provides a means to preactivate a cellular graft and that such preactivation would provide the benefits described above the Company took into consideration the following published studies :

“Low Level Laser Irradiation Precondition to Create Friendly Milieu of Infarcted Myocardium and Enhance Early Survival of Transplanted Bone Marrow Cells” Published in the Journal of Cellular and Molecular Medicine September 2009.

Study addressed: (1) whether low-level laser irradiation (LLLI) pre-treatment change the local cardiac micro-environment after myocardial infarction (MI) and (2) whether the LLLI preconditions enhance early cell survival and thus improve therapeutic angiogenesis and heart function. This study demonstrated that LLLI precondition significantly enhanced early cell survival rate of implanted bone marrow mesenchymal stem cells ( BMSCs) by 2-fold and decreased the apoptotic (cell self-destruction ) percentage of implanted BMSCs in infarcted myocardium and thus increased the number of newly formed capillaries. Mesenchymal stem cells (MSCs) are multipotent stem cells found in bone marrow that are important for making and repairing skeletal tissues, such as cartilage, bone and the fat found in bone marrow.

“In vitro effects of low-level laser irradiation for bone marrow mesenchymal stem cells: proliferation, growth factors secretion and myogenic differentiation.” Published December 2008 in Lasers in Surgery and Medicine..

This study concluded that LLLI stimulates proliferation, increases growth factors secretion and facilitates myogenic differentiation of BMSCs. Therefore, LLLI may provide a novel approach for the preconditioning of BMSCs in vitro prior to transplantation.

“Low-level laser irradiation (LLLI) promotes proliferation of mesenchymal and cardiac stem cells in culture” published in Lasers in Surgery and Medicine April 2007.

Isolation of MSCs and CSCs was performed. The cells were cultured and laser irradiation was applied. The number of MSCs and CSCs up to 2 and 4 weeks respectively, post-LLLI demonstrated a significant increase in the laser-treated cultures as compared to the control. This study demonstrates the ability of LLLI to promote proliferation of MSCs and cardiac stem cells (CSCs) in vitro.

All of the abovementioned studies were conducted by third parties unaffiliated with the Company or management of the Company.

On December 2, 2020 SYBLEU INC. (the “Company”) was assigned all right, title, and interest to intellectual property related to intratumoral administration of a combination of a chemotherapeutic agent and an immunomodulatory agent for cancer therapy ( “Cancer Therapy IP”).

The concept of the Cancer Therapy IP is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.

These rights were assigned to the Company by the Company’s Chief Executive Officer and Entest BioMedical, Inc., a California corporation controlled by the Company’s Chief Executive Officer. The aforementioned assignment constituted a contribution of intellectual property to the Company. There is no termination date of the assignment. No term or condition of the assignment would cause ownership of the intellectual property rights to revert back to David Koos and Entest BioMedical, Inc. No payment of any sort is required by to be made the Company to either David Koos or Entest BioMedical, Inc. pursuant to the assignment. The Company is not required to meet any particular benchmark or pay a royalty of any sort pursuant to this assignment.

On February 24, 2021 SYBLEU INC. ( the “Company”) and Oncology Pharma, Inc. ( “Licensee”) entered into an agreement whereby the Company granted the Licensee an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company (“Agreement”).

This intellectual property relates to intratumoral administration of a combination of a chemotherapeutic agent and an immunomodulatory agent for cancer therapy ( “Cancer Therapy IP”). The concept of the Cancer Therapy IP is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.

The term of the Agreement is fifteen years from the Effective Date.

Pursuant to the Agreement:

(a)

Licensee shall pay to the Company a non-refundable, upfront payment of six thousand five hundred shares of Oncology Pharma, Inc. common stock as a license initiation fee which must be paid within 10 days of the Effective Date of the Agreement

(b)

royalties equal to five percent (5%) of the Net Sales of any Licensed Products in a quarter.

Net Sales are defined in the Agreement as the gross invoiced amount, and/or the monetary equivalent of any other consideration actually received by Licensee and/or its sublicensees, for the transfer of a Licensed Product, less any of the following items that are itemized on the relevant invoice or which Licensee can demonstrate have been actually paid or credited with respect to such transfer.

Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the licensed intellectual property in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the licensed intellectual property in the U.S. or foreign jurisdictions but for the rights granted pursuant to this Agreement.

Oncology Pharma Inc. is a publicly traded company whose common shares trade on the OTC Pink market under the symbol ONPH.

Licenses Granted to the Company

On June 26, 2023 Sybleu Inc. ( the “Company”) was granted an exclusive worldwide license by DYO Biotechnologies, Pty, Ltd (“DYO”) to (a) to make, have made, use, offer for sale, sell, perform, have performed export and import Licensed Products and Licensed Services; (b) to practice Licensed Methods; and (c) to use Technology, all in the Field, within the Territory and during the Term (the “License”).

“Licensed Products” are defined in the License as “any product, kit, composition, or part thereof: (a) that incorporates, uses, or is enabled or derived from the use of the Technology; or (b) that is produced or enabled by a Licensed Method.”

“Licensed Services” are defined in the License as “any service performed by Company or Sublicensee for the benefit of a third party that, in whole or in part, (a) uses Technology; (b) uses Licensed Product(s); or (c) that practices or is enabled by a Licensed Method.”

“Licensed Method” is defined in the License as “any method or process that uses Technology”

“Field” is defined in the License as small molecule drug development and commercialization for human and/or animal health.

“Territory” is defined in the License as “worldwide”.

The Term of the License is the period of time beginning on the effective date of this Agreement which shall be June 26, 2023 and terminating on the last to expire Royalty Term .

“Royalty Term” is defined in the License as that period of time beginning on the first commercial sale of a Licensed Product in a given country and, expires on a country-by-country basis with respect to each Licensed Product, upon the later of: (a) the expiration, abandonment, or invalidation of the last to expire, abandoned or invalidated Valid Claim of the Patent Rights in such country; (b) the expiration of any granted statutory period of marketing exclusivity within a country; and (c) 12 years from of the date of the first commercial sale of such Licensed Product in such country.

Pursuant to the terms and conditions of the License the Company shall raise $2,000,000 US through either debt or equity financing within 2 years of execution of this Agreement (“Funding”). The Company shall enter into a research collaboration agreement with DYO upon mutually acceptable terms and conditions within 30 days of Funding (“Research Agreement).

Substantially all of the Funding shall be utilized to enable the Technology for the benefit of developing Company’s existing and future small molecule drug intellectual property. It is anticipated that this research agreement will utilize substantially all of these funds over two years. It is agreed that the Company shall exclusively possess all right, title and interest in and to including, but not limited to, the copyrights, trade secrets, trademarks and associated good will and patent rights to any and all inventions, discoveries, intellectual property and chemical structures resulting from this Research Agreement.

Pursuant to the terms and conditions of the License the Company shall pay to DYO a Royalty equal to five percent (5%) of the Net Sales ( as such term is defined in the License) of any Licensed Method, Service or Product per annum. The License also imposes an obligation upon the Company to make minimum royalty payments to DYO over the course of the Term.

Pursuant to the terms and conditions of the License the the Company paid to DYO 309,000 common shares of the Company (“Stock Payment”) and a $25,000 License Issuance Fee.

DYO shall not, directly or indirectly, offer, issue, sell, contract to sell (including without limitation short sale), grant any option for the sale of, pledge or otherwise dispose of or transfer any or all of the Stock Payment for a period of two years from the date of issuance.

Pursuant to the terms and conditions of the License Upon the occurrence of each of the following events (each a “Milestone”)), the Company shall make a cash payment (“Milestone Payment”) in the amount corresponding to such Milestone within thirty days after achievement of each Milestone:

Milestone	AMOUNT
1. Dosing of a first human patient in a Phase I or Phase I/II Clinical Trial for Licensed Product	$150,000 US
2. Dosing of a first patient in a Phase III Clinical Trial for Licensed Product	$500,000 US
3. FDA (US) Approval of a Licensed Product	$3,000,000 US
4. EMA (EU) Approval of a Licensed Product	$1,500,000 US
5. PMDA (JPN) Approval of a Licensed Product	$1,000,000 US
6. Cumulative Net Sales of Licensed Products reach $100 Million	$2,000,000 US

This License may be terminated by DYO in the event:

No licensed Method, Service or Product has been granted Patent Protection in at least one jurisdiction after the expiration of four years from execution

The sum of $2,000,000 shall not have been raised within 2 years of execution of the license

The Research Agreement shall not have been entered into as of thirty days subsequent to the Funding.

The Company shall not have achieved cumulative Net Sales of Licensed Product, Service and Methods of at least $10,000,000 as of a date that is ten years from the execution of the license

The Company shall fail to pay any consideration required under the license and such failure remains uncured for thirty days.

This License may be terminated by the Company in the event:

DYO shall be determined to not have exclusive unencumbered Patent Rights to the Technology in whole or in part.

Any other entity shall be determined to have the right- exercised or not- to utilize the Technology ( in whole or in part) to develop make, use, offer for sale, sell, perform, have performed export and import and sell products, methods and services which can reasonably be expected to be similar to or competitive with products, methods and services to be developed by the Company utilizing the rights granted by the License. .

DYO shall have failed to demonstrate during the course of due diligence to the satisfaction of the Company that the Technology can be effectively utilized for the purposes intended by this License

In the event that the Agreement is terminated pursuant to the any of the abovementioned the Stock Payment shall be promptly returned by DYO to the Company for cancellation.

Dr. Harry Lander serves as Chief Scientific Officer of the Company and is a shareholder of the Company. Dr. Harry Lander also serves as Managing Director of DYO and is a controlling shareholder of DYO.

Distribution methods of the products or services:

If circumstances allow and subject to then current market conditions and available capital, we intend to enter into licensing and/or sublicensing agreements with outside entities in order that the Company may, if the Company is successful in securing its intellectual property claims, allow it to obtain royalty income on the products and services which it may develop and commercialize.

Competitive business conditions and the Company’s competitive position in the industry and methods of competition

We are recently formed and have yet to achieve consistent revenues or profits and there can be no assurance that we will generate revenues or, if are successful, that we can do so at levels that will allow us to achieve and sustain positive cash flow and profitability and, if so, for any period of time.. The industry in which we intend to compete are highly competitive and characterized by rapid technological advancement. Many of our competitors have greater resources than we do.

We intend to be competitive by utilizing the services and advice of individuals that we believe have expertise in their field in order that we can concentrate our resources on projects in which products and services in which we have the greatest potential to secure a competitive advantage may be developed and commercialized .

To that effect, we have ~~entered~~established ~~into~~a ~~nonemployee~~Scientific ~~consulting~~Advisory ~~agreements~~Board ~~with~~considting ~~individuals~~of members who we believe have a high level of expertise in ~~their~~ their professional fields and who have agreed to provide counsel and assistance to us in (a) determining the viability of proposed ~~projects~~ projects (b) obtaining financing for projects and (c) obtaining the resources required to initiate and complete a project in the most cost effective and rapid manner.

These individuals are as follows:

SCIENTIFIC ADVISORY BOARD MENBERS

Dr. Steven E. Hake, M.D.

Dr. Hake obtained his medical degree from The Chicago Medical School. Dr. Hake has been certified by American Board of Radiology since June 1992. Dr. Hake’s professional affiliations are with the Alpha Omega Alpha Honorary Medical Society and the American College of Radiology.

~~On July~~ 7, 2020 the Company entered into an agreement with Dr. Stephen Hake whereby Dr. Hake agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Hake 40,000 of the Company’s common shares within 20 days of the execution of the Agreement.

Pursuant to the Agreement Dr. Hake shall advise the Company on various matters regarding biotechnology for the Company. Dr. Hake Member shall refer Company to appropriate researchers on specific topics and provide input on research data the company is developing. The frequency and timing of such services shall be established on a mutually agreeable basis. In the event Dr. Hake is requested to provide research services, such services will be negotiated separately between Dr. Hake and the Company.

The Term of the Agreement commenced on July 8, 2020 and the Agreement shall expire on July 7,2021. The Term of the Agreement may be extended by mutual agreement between the parties. Since July 8, 2021 Dr. Hake has continued to serve as a member of the Company’s Scientific Advisory Board.

40,000 common shares of SYBLEU INC. were issued to Dr. Hake on July 8, 2020 as consideration for his service as a member of the Company’s Scientific Advisory Board.

Dr. Jason E. Garber, MD.

On July 7, 2020 the Company entered into an agreement with Dr. Jason Garber whereby Dr. Garber agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Garber 25,000 of the Company’s common shares within 20 days of the execution of the Agreement.

Pursuant to the Agreement Dr. Garber shall advise the Company on various matters regarding biotechnology for the Company. Dr. Garber Member shall refer Company to appropriate researchers on a specific topics and provide input on research data the company is developing. The frequency and timing of such services shall be established on a mutually agreeable basis. In the event Dr. Garber is requested to provide research services, such services will be negotiated separately between Dr. Garber and the Company.

The Term of the Agreement commenced on July 8, 2020 and the Agreement shall expire on July 7,2021. The Term of the Agreement may be extended by mutual agreement between the parties. Since July 8, 2021 Dr. Garber has continued to serve as a member of the Company’s Scientific Advisory Board.

25,000 common shares of SYBLEU INC. were issued to Dr. Garber on July 8, 2020 as consideration for his service as a member of the Company’s Scientific Advisory Board.

Dr. Garber obtained his medical degree from The University of Texas Health Science Center at San Antonio. Dr. Garber is Board Certified in Neurological Surgery by the American Board of Neurological Surgery

Dr. Garber was awarded a Cloward Fellowship Award in 2001 and has authored the following papers in the following publications:

Hassenbusch, SJ, Garber, JE: “Alternative Intrathecal Agents for Pain,” Neuromodulation, Volume 2, Number 2, 1999 89-95.

Garber, JE, Hassenbusch, SJ: “Innovative Intrathecal Analgesics,” Pain surgery, Burchiel, K (ed): In Press.

Garber, JE, Hassenbusch, SJ: “Interventional Pain Management: Can Charges be Effectively Minimized without Compromising Quality?” Pain Digest: In Press.

Garber, JE, Hassenbusch, SJ: Neurosurgical Operations on the Spinal Cord. Bonica’s Management of Pain, 3rd Edition, Loeser, JD (ed), Medica, PA: Williams and Wilkins, 1998: In Press.

Garber, JE, Hassenbusch, SJ: “Spinal Administration of Non-Opiate Analgesics in the Management of Pain,” Interventional Pain Management, 2nd Edition, Waldman, SD (ed), WB Saunders: In Press

Nguyen H, Garber JE, Hassenbusch SJ: Spinal Analgesics. In: Staats P and Fleisher LA (eds). Anesthesiology Clinics of North America, Saunders: Philadelphia, pp. 805-816, 2003.

Garber, JE, Thalgott JS, Christensen SD: Anterior Lumbar Interbody Fusion via the Anterior Retroperitoneal Approach: Strategic Tactics for Avoiding Complications. The NNI Journal, Volume 2, Issue 3, 2006 62-65.

Garber, JE, Thalgott JS, Fogarty M, Caiazza S: Dynamic Stabilization of the Lumbar Spine: Past, Present, and Future Innovations. The NNI Journal, Volume 3, Issue 1, 2007 pp. 84-87.

Garber, JE, Saxena RC, Malone K: The Identification and Treatment of a Lumbar Plasmacytoma: A Case Report and Topic Review. The NNI Journal, Volume 3, Issue 3, 2007 pp. 135-139

Garber, JE, Malone K: Utilizing a Lateral Extracavitary Approach for Failed Lumbar Spine Fusion Procedures: A Case Study with Imaging Considerations in Lumbar Fusions. The NNI Journal, Volume 4, Issue pp. 14-15.

Garber, JE, Christian G, Serrano S, Malone K: Surgical Treatment of Intradural Extramedullary Spine Tumors. The NNI Journal, Volume 5, Issue 1, April 2009.

Garber, JE, Christian G, Serrano S, Malone, K: Nail-Gun Misfire Resulting in Penetrating Intracranial Injury. The NNI Journal, Volume 5, Issue 1, April 2009.

Garber, JE, Christian G, Serrano S, Malone, K: Craniocervical Fixation Series and Review of Literature. The NNI Journal, Volume 6, Issue 1, Jan 2010.

Dr. Garber has made the following professional presentations:

1. 1999 Congress of Neurological Surgeons (CNS) Meeting, Boston, MA. Oral Presentation, Section on Pain II: Interventional Pain Management: Can Charges Be Effectively Minimized Without Compromising Quality?

2. 2000 Neurosurgery + Science + Management Symposium, New Orleans, LA. Oral Presentation: Cancer and Non-cancerous Pain Management.

3. 2001 Congress of Neurological Surgeons (CNS) Meeting, San Diego, CA. Poster Presentation: Extralaminar Posterior Cervical Dorsal Ramisectomy: A Modified Surgical Approach for the Treatment of Cervical Dystonia (Spasmodic Torticollis).

4. 2005 Medical Education Resources Making Sense of Spine Surgery Seminar, Las Vegas, NV. Oral Presentation: Spinal Disorders: Cervical Conditions and Treatment. Demonstration: Cervical Construct Demonstration: Atlantis Vision Cervical Plate.

5. Minimally Invasive Spinal Surgery. Sunrise Hospital and Medical Center Grand Rounds, June 1, 2005.

6. Oral Presentation: One Neurosurgeon’s Experience with STALIF, Newport Beach, CA, November 2007.

7. EuroSpine: What is the Role of Mystique plating and Bioresorbable Technology in anterior cervical Fusion Procedures? Bressels, Belgium, 2007.

8. Oral Presentation: Novel Minimally Invasive Spine Techniques, Las Vegas, NV, January 2008.

9. International Meeting on Advanced Spine Techniques, Hong Kong, China, July 2008. Poster Presentation: A Comparison of the Surgical Efficacy of ALIF and XLIF® L4-5 Fusion Procedures with Posterior Fixation.

10. Congress of Neurological Surgeon’s 2008 Annual Meeting, Orlando, FL, September 2008. Poster Presentation: A Comparison of the Surgical Efficacy of ALIF and XLIF® L4-5 Fusion Procedures with Posterior Fixation.

11. North American Neuromodulation Society (NANS) 13th Annual Meeting, Las Vegas, NV, December 3-6 2009. Paper Presentation: Selective Dermatome Activation, Using a Novel Five-Column Spinal Cord Stimulation Paddle Lead: A Case Series.

12. International Society for the Advancement of Spine Surgery – 2 nd Asia Pacific Conference (2010 APSAS), Sanya, China, January 14-17 2010. Paper Presentation: Direct Lateral Approach Corpectomy for Severe Kyphotic Deformity Correction.

13. The Role of Permanent Vascular Protection in Anterior Spine Instrumentation – 39th Annual Symposium, Orlando FL. March 16-19, 2011. A Review of Ten Same Lumbar Level Reoperations, Society of Clinical Vascular Surgery.

14. International Society for the Advancement of Spine Surgery – Annual Meeting (SAS, 2011), Las Vegas. Poster Presentation: A Multi-center Retrospective Evaluation of a Cervical Integrated Interbody System.

15. Conejo Valley Journal Club, Sherman Oaks, CA. January, 2015. Oral Presentation: Benefits of an Integrated Interbody Device over Spacers and Plates.

16. Society for Minimally Invasive Spine Surgery Global Forum ’15 – Las Vegas, NV. November 6, 2015. Minimally Invasive Stabilization: A 5 year Level 1 Study of Spinal Stenosis Disease Management.

17. International Society for the Advancement of Spine Surgery, Metro Toronto, Canada, April 11-13, 2018. Clinical Experience of Integrated Interbody Fusion in Multi-level Cervical Fusion.

18. Society for Minimally Invasive Spine Surgeons Annual Forum ’18, Las Vegas Nevada. Multi-level Cervical Constructs in Clinical Practice using Integrated Interbody Fusion.

19. Society for Minimally Invasive Spine Surgeons Annual Forum ’18, Las Vegas Nevada. Interspinous Decompression Devices – Do They Have a Role?

20. Congress of Neurological Surgery’s 2018 annual meeting, Houston Texas, October 6-10, 2018. Integrated Interbody Fusion in Multi-level Cervical Constructs in Clinical Practice.

21. Congress of Neurological Surgery’s 2018 annual meeting, Houston Texas, October 6-10, 2018. Swan Neck Deformity Correction with Multilevel Anterior Cervical Integrated Cages.

22. International Spinal Deformity Symposium 4th Annual, November/December 2018. Multilevel Cervical Constructs in Clinical Practice using Integrated Interbody Fusion.

23. International Society for the Advancement of Spine Surgery, Anaheim, California, April 3, 2019. Oral poster presentation: Cervical spinal deformity correction utilizing an integrated interbody fusion devices from a single anterior approach.

24. North American Spine Society 34th annual meeting, Chicago, Illinois, September 25-28, 2019. Poster presentation: Integrated Interbody Fusion in Multilevel Cervical Constructs in Clinical Practice.

25. American College of Surgeons, San Francisco, California, October 28, 2019. Oral presentation: Integrated Interbody Fusion in Multi-level Cervical Constructs in Clinical Prectice.

Dr. Garber is affiliated with the Las Vegas Neurosurgical Institute in Las Vegas, Nevada.

On July 7, 2020 the Company entered into an agreement with Dr. Stephen Garber whereby Dr. Garber agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Garber 25,000 of the Company’s common shares within 20 days of the execution of the Agreement.

The Term of the Agreement commenced on July 8, 2020 and the Agreement shall expire on July 7,2021. The Term of the Agreement may be extended by mutual agreement between the parties. Since July 8, 2021 Dr. Garber has continued to serve as a member of the Company’s Scientific Advisory Board.

25,000 common shares of SYBLEU INC. were issued to Dr. Garber on July 8, 2020 as consideration for his service as a member of the Company’s Scientific Advisory Board.

The Company is currently continuing to search for other experts to serve on the Company’s Scientific Advisory Board.

Principal Products and Services:

The Company is currently focused upon:

(a)

developing drugs for treating cancer in companion animals

(b)

examining the role of Artificial Intelligence and Machine Learning in clinical diagnostics and

(c)

development of disposable medical devices

Sources and availability of raw materials and the names of principal suppliers

The supplies and materials required to conduct our operations are available through a wide variety of sources and may be obtained through a wide variety of sources.

Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including duration

~~The Company possesses no patents or trademarks.~~Patents:

The Company has ~~filed~~purchased ~~patent~~a ~~applications~~50% ~~with~~interest in and to inventions granted the following patents by the United States Patent and Trademark Office ~~seeking patent protection for the following inventions:~~.

~~"Cancer~~US ~~therapy~~Patent byUS11377442B2 ~~intratumoral~~(Small ~~injection~~molecule ofagonists aand ~~chemotherapeutic~~antagonists ~~agent~~of inNR2F6 ~~combination with a bioactive immunostimulatory agent"~~activity)

~~“Improving~~US ~~Quality~~Patent US US10472351B2 (Small molecule agonists and antagonists of aNR2F6 ~~Cellular~~activity ~~Graft~~in animals.”

No assurance can be given that patent protection will be obtained for the abovementioned inventions.

The Company is not party to any agreement which would oblige the Company to pay any royalties.

~~The term~~Royalty ~~of the Agreement is fifteen years from the Effective Date.~~Agreements:

“Licensed Method” is defined in the License as “any method or process that uses Technology”

“Field” is defined in the License as small molecule drug development and commercialization for human and/or animal health.

“Territory” is defined in the License as “worldwide”.

The Term of the License is the period of time beginning on the effective date of this Agreement which shall be June 26, 2023 and terminating on the last to expire Royalty Term .

Pursuant to the terms and conditions of the License the l Company paid to DYO 309,000 common shares of the Company (“Stock Payment”).

Milestone	AMOUNT
1. Dosing of a first human patient in a Phase I or Phase I/II Clinical Trial for Licensed Product	$150,000 US
2. Dosing of a first patient in a Phase III Clinical Trial for Licensed Product	$500,000 US
3. FDA (US) Approval of a Licensed Product	$3,000,000 US
4. EMA (EU) Approval of a Licensed Product	$1,500,000 US
5. PMDA (JPN) Approval of a Licensed Product	$1,000,000 US
6. Cumulative Net Sales of Licensed Products reach $100 Million	$2,000,000 US

This License may be terminated by DYO in the event:

No licensed Method, Service or Product has been granted Patent Protection in at least one jurisdiction after the expiration of four years from execution

The sum of $2,000,000 shall not have been raised within 2 years of execution of the license

The Research Agreement shall not have been entered into as of thirty days subsequent to the Funding.

The Company shall not have achieved cumulative Net Sales of Licensed Product, Service and Methods of at least $10,000,000 as of a date that is ten years from the execution of the license

The Company shall fail to pay any consideration required under the license and such failure remains uncured for thirty days.

This License may be terminated by the Company in the event:

DYO shall be determined to not have exclusive unencumbered Patent Rights to the Technology in whole or in part.

DYO shall have failed to demonstrate during the course of due diligence to the satisfaction of the Company that the Technology can be effectively utilized for the purposes intended by this License

In the event that the Agreement is terminated pursuant to the any of the abovementioned the Stock Payment shall be promptly returned by DYO to the Company for cancellation.

Need for any government approval of principal products or services, effect of existing or probable governmental regulations on the business.

The US Food and Drug Administration (“FDA”) and foreign regulatory authorities will regulate our proposed products as drugs or biologics, , depending upon such factors as the use to which the product will be put, the chemical composition, and the interaction of the product on the human body. In the United States, products that are intended to be introduced into the body will generally be regulated as drugs, while tissues and cells intended for transplant into the human body will be generally be regulated as biologics.

Our domestic human drug and biological products will be subject to rigorous FDA review and approval procedures. After testing in animals, an Investigational New Drug Application (“IND”) must be filed with the FDA to obtain authorization for human testing. Extensive clinical testing, which is generally done in three phases, must then be undertaken at a hospital or medical center to demonstrate optimal use, safety, and efficacy of each product in humans.

Phase I

Phase 1 trials are designed to assess the safety (pharmacovigilance), tolerability, pharmacokinetics, and pharmacodynamics of a drug. These trials are often conducted in an inpatient clinic, where the subject can be observed by full-time staff. The subject who receives the drug is usually observed until several half-lives of the drug have passed. Phase I trials normally include dose-ranging, also called dose escalation, studies so that the appropriate dose for therapeutic use can be found. The tested range of doses usually are a fraction of the dose that causes harm in animal testing and involve a small group of healthy volunteers. However, there are some circumstances when real patients are used, such as patients who have end-stage disease and lack other treatment options.

Phase II

Phase II trials are designed to assess how well the drug or biologic works, as well as to continue Phase I safety assessments in a larger group of volunteers and patients. Phase II trials are performed on larger groups.

Phase III

Phase III trials are aimed at being the definitive assessment of how effective the product is in comparison with current best standard treatment and to provide an adequate basis for physician labeling. Phase III trials may also be conducted for the purposes of (i) "label expansion" (to show the product works for additional types of patients/diseases beyond the original use for which the drug was approved for marketing or (ii) to obtain additional safety data, or to support marketing claims for the product.

On occasion Phase IV (Post Approval) trials may be required by the FDA. Phase IV trials involve the safety surveillance (pharmacovigilance) and ongoing technical support of a drug after it receives permission to be sold. The safety surveillance is designed to detect any rare or long-term adverse effects over a much larger patient population and longer time period than was possible during the Phase I-III clinical trials.

All phases, must be undertaken at a hospital or medical center to demonstrate optimal use, safety, and efficacy of each product in humans. Each clinical study is conducted under the auspices of an independent Institutional Review Board (“IRB”). The IRB will consider, among other things, ethical factors, the safety of human subjects, and the possible liability of the institution. The time and expense required to perform this clinical testing can far exceed the time and expense of the research and development initially required to create the product. No action can be taken to market any therapeutic product in the United States until an appropriate New Drug Application (“NDA”) or Biologic License Application (“BLA”) or has been approved by the FDA. FDA regulations also restrict the export of therapeutic products for clinical use prior to NDA or BLA approval.

Even after initial FDA approval has been obtained, further studies may be required to provide additional data on safety or to gain approval for the use of a product as a treatment for clinical indications other than those initially targeted. In addition, use of these products during testing and after marketing could reveal side effects that could delay, impede, or prevent FDA marketing approval, resulting in FDA-ordered product recall, or in FDA-imposed limitations on permissible use.

The FDA regulates the manufacturing process of pharmaceutical products, and human tissue and cell products, requiring that they be produced in compliance with Current Good Manufacturing Practices (“cGMP”) . The FDA also regulates the content of advertisements used to market pharmaceutical products. Generally, claims made in advertisements concerning the safety and efficacy of a product, or any advantages of a product over another product, must be supported by clinical data filed as part of an NDA or an amendment to an NDA, and statements regarding the use of a product must be consistent with the FDA approved labeling and dosage information for that product.

Sales of drugs and biologics outside the United States are subject to foreign regulatory requirements that vary widely from country to country. Even if FDA approval has been obtained, approval of a product by comparable regulatory authorities of foreign countries must be obtained prior to the commencement of marketing the product in those countries. The time required to obtain such approval may be longer or shorter than that required for FDA approval.

~~Amount~~The ~~spent~~Center ~~during~~for Veterinary Medicine (“CVM”) at the ~~fiscal~~United ~~year~~States ~~ended~~Food ~~June~~and 30Drug Administration (“FDA”) regulates animal pharmaceuticals under the Food, ~~2022~~Drug and Cosmetics Act. Manufacturers of animal health pharmaceuticals must show their products to be safe, effective and produced by a consistent method of manufacture. The new animal drug approval process is complicated. Before a new animal drug may receive FDA approval, the sponsor must establish that the new animal drug is safe and effective. Drug sponsors must submit a New Animal Drug Application (NADA) along with supporting data, including all adverse effects associated with the drug's use. The NADA must also include information on ~~research~~the drug's chemistry; composition and ~~development~~component ~~activities~~ingredients; manufacturing methods, facilities, and controls; proposed labeling; analytical methods for residue detection and analysis if applicable; an environmental assessment; and other information. The sponsor of a new animal drug is responsible for submitting all appropriate data to establish effectiveness and safety. If the drug product is intended for use in a food-producing animal, residues in food products must also be established as safe for human consumption. FDA review of the NADA submitted by drug sponsors is extremely detailed and comprehensive. The CVM’s basis for approving a drug application is documented in a Freedom of Information Summary. . We will be required to conduct post-approval monitoring of FDA approved pharmaceutical products and to submit reports of product quality defects, adverse events or unexpected results to the CVM’s Surveillance and Compliance group. No assurance may be given any new animal drug product which the Company may develop will be approved by the FDA to be marketed and sold. Regulatory authorities in countries outside of the United States and Europe also have requirements for approval of veterinary drug candidates with which we must comply prior to marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure that we will be able to obtain regulatory approval in any other country.

~~During~~Amount spent during the fiscal year ended June 30, ~~2022~~2023 ~~we expended $5,058~~ on research and development activities.

During the fiscal year ended June 30, 2023 we expended $85,489 on research and development activities.

Costs and effects of compliance with environmental laws (federal, state and local)

SYBLEU has not incurred any unusual or significant costs to remain in compliance with any environmental laws and does not expect to incur any unusual or significant costs to remain in compliance with any environmental laws in the foreseeable future.

Number of total employees and number of full-time employees

As of July 1631, ~~2022~~2023 the Company has 2 employees of which each of them is part time.

Item 2. Properties

The Company utilizes approximately ~~2,300~~500 square feet of office space at ~~4700~~1034 ~~Spring~~Throggs ~~Street,~~Neck ~~Suite 304~~Expressway, LaBronx ~~Mesa~~NY ~~California,~~10465 ~~91941~~ provided to the Company by anJoseph ~~entity~~G. ~~controlled~~Vaini, by the Company’s ~~Chief~~sole ~~Executive~~officer ~~Officer~~and director, on a month to month basis free of charge. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space.

Item 3. Legal Proceedings

There are no material pending legal proceedings to which the Company is a party or of which any of the Company’s property is the subject.

Item 4. Submission of Matters to a Vote of Security Holders

No matter was submitted during the fourth quarter of the fiscal year covered by this report to a vote of security holders, through the solicitation of proxies or otherwise.

1215

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

~~There~~Prior ~~has~~to ~~never~~March ~~been~~2023 ~~and there currently is~~ no public market existed for our securities. AIn ~~registered~~March ~~broker-~~2023 ~~dealer has applied to~~ the ~~Financial~~common ~~Industry Regulatory~~shares ~~Authority (“FINRA”) in order to initiate quotations~~ of ~~our~~the ~~common~~Company ~~shares~~began ontrading over the “Pink” market ~~Market~~ operated by OTC Markets Group ~~however~~under wethe ~~can~~symbol ~~provide no assurance that our shares will be traded or, if traded, that a public market will materialize~~SYBE.

The ~~stockholders'~~Company’s common ~~equity~~stock ~~section~~is a "penny stock," as defined in Rule 3a51-1 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the ~~Company~~penny ~~contains~~stock market. The broker-dealer also must provide the ~~following~~customer ~~classes~~with current bid and offer quotations for the penny stock, the compensation of ~~capital~~the broker-dealer and its sales person in the transaction, and monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that the broker-dealer, not otherwise exempt from such rules, must make a special written determination that the penny stock is suitable for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure rules have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules. So long as ~~July~~the 16common stock of the Company is subject to the penny stock rules, ~~2022:~~it may be more difficult to sell common stock of the Company.

~~Common~~The ~~stock,~~stockholders’ $equity ~~0.0001~~section ~~par~~of ~~value;~~the ~~100,000,000~~Company ~~shares~~contains ~~authorized:~~the ~~10,418,000~~following ~~shares~~class ~~issued~~of ~~and~~capital ~~outstanding.~~stock as of July 31, 2023:

Common stock, $ 0.0001 par value; 100,000,000 shares authorized: 10,613,492 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company'’s stockholders, a ratable share in the assets of the ~~Corporation~~Company.

AsBelow is the range of ~~September~~high ~~20,~~and ~~20221~~low ~~there~~bid ~~were~~information ~~245~~for ~~holders~~our ofcommon equity for each quarter within the last two fiscal years that a public market has existed for our ~~Common~~common ~~Stock~~equity. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.

July 1, 2022 to June 30, 2023	HIGH		LOW
Third Quarter	$	0.1	$	0.1
Fourth Quarter	$	0.2899	$	0.02

As of July 31, 2023 there were approximately 245 holders of our Common Stock.

Dividends

No cash dividends were paid during the fiscal year ending June 30, ~~2022~~2023. We do not expect to declare cash dividends in the immediate future.

Recent Sales of Unregistered Securities

~~None~~On December 12, 2022 the Company issued 3,000,000 common shares (“Shares”) to Joseph G Vaini pursuant to an agreement whereby Joseph G. Vaini agreed to serve as President, Chief Executive Officer, Secretary, Chief Financial Officer and Secretary, Treasurer and Principal Accounting Officer of the Company.

On December 12, 2022 the Company issued 3,000,000 common shares (“Shares”) to Harry Lander pursuant to an agreement whereby Harry Lander agreed to serve as Chief Scientific Officer of the Company.

On December 13, 2022 the Company cancelled 6,113,508 common shares owned by David Koos, the Company’s previous sole officer and director, and a company controlled by David Koos. Effective December 13, 2022 David Koos resigned as a Director of the Company and also resigned from any and all other offices he had held of the Company (“Resignation”) . In connection with his Resignation Koos has returned any and all common shares directly or indirectly held by Koos to the Company for cancellation. Also in connection with his Resignation Koos and the Company have entered into an agreement ( “Separation Agreement”) whereby the Company shall pay Koos the sum of $10,000.

On June 28, 2023 the Company issued 309,000 common shares ( “Shares”) to DYO Biotechnologies, Pty, Ltd pursuant to the terms and conditions of an agreement entered into by and between DYO Biotechnologies, Pty, Ltd and the Company.

All Shares issued were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

Item 6. Selected Financial Data

As we are a “smaller reporting company” as defined by Rule 229.10(f)(1), we are not required to provide the information required by this Item.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

As of June 30, ~~2021~~2023 we had ~~Cash~~cash of $143,~~297~~786 and as of June 30, 2022 we had ~~Cash~~cash of $66,850. The decrease in cash of 94% is primarily attributable to (a) $15,000 paid out to Joanne Vaini whereby Joanne Vaini agreed to provide bookkeeping services for the Company for the period beginning January 9, 2023 and ending July 9, 2024 (“Agreement”) for total consideration consisting of $15,000 (b) $12,500 paid to Wilson Davis and Co., a registered Broker Dealer, for assistance in obtaining DTC eligibility for the Company’s common shares. DTC Eligibility means that a public company's securities are able to be deposited through Depository Trust and Clearing Corporation and (c) $25,000 paid to DYO Biotechnologies, Pty, Ltd pursuant to the terms and conditions of a license granted to the Company by DYO Biotechnologies, Pty, Ltd.

~~The~~Joanne ~~1ncrease~~Vaini inis ~~cash~~the spouse of ~~approximately~~the ~~367.58%~~Company’s isChief ~~primarily~~Executive ~~attributable~~Officer toJoseph aG. ~~net~~Vaini. ~~increase~~Dr. inHarry ~~aggregate~~Lander ~~Notes~~serves ~~Payable~~as ofChief ~~$131,081~~Scientific ~~offset by~~Officer ~~expenses~~of ~~incurred~~the inCompany ~~the~~and ~~operation~~is a shareholder of the Company’s. ~~business~~Dr. Harry Lander also serves as Managing Director of DYO and is a controlling shareholder of DYO Biotechnologies, Pty, Ltd.

As of June 30, ~~2021~~2023 we had ~~Investment~~Prepaid ~~Securities~~Expenses of $~~185~~24,762 ~~250~~ and as of June 30, 2022 we had ~~Investment~~Prepaid ~~Securities~~Expenses of ~~$9,529~~0. Prepaid Expenses recognized as of June 30, 2023 are attributable to:

~~The~~(a) ~~decrease~~3,000,000 incommon ~~Investment~~shares ~~Securities~~issued ofto ~~approximately~~Joseph ~~95%~~G isVaini, ~~attributable to~~ the ~~revaluation~~Company’s asChief ofExecutive ~~June 30~~Officer, ~~2022~~pursuant ofto ~~6,500~~an ~~common~~employment ~~shares~~agreement to ofbe ~~Oncology~~expensed ~~Pharma,~~over ~~Inc. at~~ the ~~closing~~life ~~price~~ of the ~~common shares on the OTC Pink market.~~agreement

As(b) ~~of June 30~~3,000,000 ~~2021~~common weshares ~~had~~issued ~~Notes~~to ~~Payable~~Dr. ~~Related~~Harry ~~Party of $8~~Lander,~~919~~ ~~and~~the ~~Notes~~Company’s ~~Payable~~Chief ofScientific ~~$0 whereas as of June 30~~Officer, ~~2022~~pursuant weto ~~had~~an ~~Notes~~employment ~~Payable~~agreement ~~Related~~expensed ~~Party~~over ofthe $0life ~~and Notes Payable~~ of ~~$140,000.~~the agreement.

As(c) ~~of June 30~~$15,000 ~~2021~~prepaid wepursuant ~~had~~to ~~Interest~~an ~~Accrued~~agreement ~~but~~with ~~Unpaid~~Joanne ofVaini 0to ~~and~~be asexpensed ofover ~~June~~the ~~30,~~life ~~2022 we had Interest Accrued but Unpaid~~ of ~~$13,253~~the ~~consisting completely of interest accrued but yet to be paid on Notes Payable~~agreement.

13On December 9, 2022 an agreement (“Agreement”) was entered into by and between Sybleu Inc ( the “Company”) and Joseph G. Vaini (“Vaini”) whereby Vaini has agreed to serve as President, Chief Executive Officer, Secretary, Chief Financial Officer and Secretary, Treasurer and Principal Accounting Officer of the Company subject to the authority of the Company's Board of Directors (the “BOD”). Vaini shall perform such duties commensurate with his offices and as directed the BOD.

AsThe Term of ~~June~~this ~~30,~~Agreement ~~2022~~shall ~~Income~~commence ~~Taxes~~on ~~payable~~December ~~were~~13, ~~paid~~2022 ~~down~~and inshall ~~the~~expire ~~amount~~on ofDecember ~~$10~~13,~~429~~ ~~reducing~~2023 ~~Income~~unless ~~Taxes~~sooner ~~Payable~~terminated byin ~~approximately 48% from~~accordance ~~Income~~with ~~Taxes~~specified ~~Payable~~provisions ~~recognized~~contained ~~as of June 30, 2021~~therein.

As ofsole ~~June~~compensation ~~30,~~for ~~2021~~performing wehis ~~recognized~~duties ~~Unearned~~pursuant ~~Income~~to ofthe ~~$173,398~~Agreement ~~and~~Vaini asreceived ~~of June 30~~3,000,000 ~~2022~~of wethe ~~recognized~~Common ~~Unearned~~Shares ~~Income~~ of ~~$161,699.~~the ~~Unearned~~Company ( ~~income~~“Vaini ~~recognized~~Stock byPayment”).Vaini ~~the~~has ~~Company~~agreed isthat ~~completely~~for ~~attributable~~a toperiod ~~$177,~~of ~~450~~three inyears ~~licensing~~from ~~fees~~December ~~paid~~9, to2022 ~~the~~Vaini ~~Company~~shall ~~during~~not ~~the~~directly ~~quarter ended~~or ~~March~~indirectly, 31offer, ~~2021~~issue, ~~which~~sell, ~~are~~contract ~~being~~to ~~recognized~~sell ~~over~~(including, ~~the~~without ~~term~~limitation, ofany ~~the~~short ~~license.~~sale), ~~The~~grant ~~decrease~~any inoption ~~Unearned~~for ~~Income~~the sale of, ~~6.75%~~pledge, or isotherwise ~~attributable~~dispose ~~to recognition~~ of ~~these~~or ~~fees~~transfer asthe ~~earned~~Vaini asstock ~~required pursuant to Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606)~~payment.

~~The~~On ~~Company~~December ~~recognized~~9, ~~Revenue~~2022 ofan ~~$11,700~~agreement ~~during~~(“Agreement”) ~~the~~was ~~year~~entered ~~ended~~into ~~June~~by ~~30,~~and ~~2022~~between asSybleu ~~opposed~~Inc. to( ~~Revenue~~the of“Company”) ~~$4,052~~and Harry ~~during~~Lander ~~same~~(“Lander”) ~~period~~whereby ~~ended~~Lander ~~2021. Revenue~~has ~~was~~agreed ~~attributable~~ to ~~$177,~~serve ~~450~~as inChief ~~licensing~~Scientific ~~fees~~Officer ~~paid~~of to the Company ~~during~~subject to the ~~quarter~~authority of ~~ended~~the ~~March~~Company's ~~31,~~Board ~~2021~~of ~~which~~Directors ~~are being recognized over~~ (the ~~term~~“BOD”). ofLander’s ~~the~~duties ~~license.~~will include:

~~Net~~Identifying ~~Loss~~and ~~before~~introducing ~~taxes~~to ~~for~~ the ~~Year~~Company ~~ended~~Contract ~~June~~Research ~~30 2022 was 204% greater than the Net Loss before taxes recognized for the same period ended 2021~~Organizations. ~~This was primarily attributable to $175,721 of Unrealized Loss on Investment Securities recognized during the Year ended 2022.~~

~~Operating~~Identifying ~~Loss~~and ofintroducing ~~$56,374 recognized during the Year ended June 30, 2022 was approximately 36% less than Operating Loss recognized during the same period ended 2021. This is primarily attributable~~ to the ~~recognition~~Company ~~during~~potential ~~the~~strategic ~~Year ended June 30, 2021 of higher consulting costs as compared to the same period ended 2022~~partners.

AsIdentifying ~~of June 30, 2022 we had $66,850 in cash on hand~~ and ~~current~~introducing ~~liabilities of $164,640 such liabilities consisting of Income Tax Payable, Notes Payable, and Accrued Expenses. We feel we will not be able~~ to ~~satisfy our cash requirements over~~ the ~~next~~Company ~~twelve~~potential ~~months~~members ~~and shall be required to seek additional financing. Management plans to raise additional funds by obtaining governmental and nongovernmental grants as well as offering securities~~ for ~~cash. Management has yet to decide what type of offering~~ the Company’s ~~will~~Scientific ~~use~~Advisory ~~or how much capital the Company will raise~~Board. There is no guarantee that the Company will be able to raise any capital through any type of offerings. Management can give no assurance that any governmental or nongovernmental grant will be obtained by the Company despite the Company’s best efforts.

AsAssisting ~~of June 30, 2022~~ the Company ~~was~~in ~~not~~patent ~~party~~application toand ~~any binding agreements which would commit SYBLEU to any material capital expenditures~~prosecution.

The Term of this Agreement shall commence on December 9, 2022 and shall expire on December 8, 2025 unless sooner terminated in accordance with specified provisions contained therein.

As sole compensation for performing his duties pursuant to the Agreement Lander received 3,000,000 of the Common Shares of the Company (“Lander Stock Payment”).Lander has agreed that for a period of three years from December 9, 2022 Lander shall not directly or indirectly, offer, issue, sell, contract to sell (including, without limitation, any short sale), grant any option for the sale of, pledge, or otherwise dispose of or transfer the Lander stock payment.

On January 8, 2023 an agreement was entered into by and between Joanne Vaini and the Company whereby Joanne Vaini shall assist the Company with entry and updating of financial records in Quickbooks. The term of this agreement commenced on January 9, 2023 and shall expire on July 9, 2024

As of June 30, 2023 we had Investment Securities of $1,920 and as of June 30, 2022 we had Investment Securities of $9,529.

The decrease in Investment Securities of approximately 80% is attributable to the revaluation as of June 30, 2023 of 6,500 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market.

As of June 30, 2023 we had Acquired Intangible Assets ( net of Amortization) of $300,000 and as of June 30, 2022 we had Acquired Intangible Assets ( net of Amortization) of $0.

Acquired Intangible Assets ( net of Amortization) as of June 30, 2023 consists of intellectual property purchased from Zander Biologics, Inc. On June 30, 2023 the Company entered into an agreement whereby the Company purchased from Zander Biologics, Inc. a 50% interest in

(a)the invention disclosed in US Patent US11377442B2 (Small molecule agonists and antagonists of NR2F6 activity), all patent rights to the invention described in US Patent US11377442B2 as well as all trade secrets, trademarks and associated good will to the invention described in US Patent US11377442B2 and

(b) the invention disclosed in US Patent US US10472351B2 (Small molecule agonists and antagonists of NR2F6 activity in animals), all patent rights to the invention described in US Patent US10472351B2 as well as all trade secrets, trademarks and associated good will to the invention described in US Patent US10472351B2.

(“IP Rights”).

The IP rights are to patent protected small molecule compounds which compounds have been found to modulate the immune system.

As of June 30, 2023 we had Notes Payable of $477,500 and as of June 30, 2022 we had Notes Payable of $140,000. The increase in Notes Payable of 241% is primarily attributable to:
(a) a $300,000 Promissory Note issued to Zander Biologics as consideration for the purchase of intellectual property

(b) a $25,000 Promissory Note issued to Bostonia Partners during the quarter ended June 30, 2023

As of June 30, 2023 we had expenses accrued but unpaid of 15,500 and as of June 30, 2022 we had expenses accrued but unpaid of $452. The increase is primarily attributable to:

(a)

expenses of $9,221 recognized during the period in connection with an agreement with a third party to provide on demand telephone support to the Company related to any and all hardware and software computer issues

(b)

expenses of $3,000 incurred in connection with the design of the Company’s website

(c)

$920 in legal/ patent prosecution fees

(d)

$620 in Transfer Agent fees

As of June 30, 2023 we had Interest Accrued but Unpaid of $27,476 consisting completely of interest accrued but yet to be paid on Notes Payable and as of June 30, 2022 we had Interest Accrued but Unpaid of $13,253 consisting completely of interest accrued but yet to be paid on Notes Payable.

The increase in Interest Accrued but Unpaid of approximately 107% is attributable to $10,352 of interest accrued but not paid on $140,000 in Notes payable during the nine months ended June 30, 2023 as well as $3,870 interest accrued but not paid on $177,500 in Notes payable during the quarter ended June 30, 2023.

As of June 30, 2023 we recognized Unearned Income of $150,002 and as of June 30, 2022 we recognized Unearned Income of $161,699. Unearned income recognized by the Company is completely attributable to $177, 450 in licensing fees paid to the Company during the quarter ended June 30, 2021 which are being recognized over the term of the license. The decrease in Unearned Income is attributable to recognition of these fees as earned as required pursuant to Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606).

The Company recognized revenue of $11,696 during the tear ended June 30, 2023 and revenue of $11,700 for the same period ended 2022. In both periods revenue was attributable to $177, 450 in licensing fees paid to the Company during the quarter ended June 30, 2021 which are being recognized over the term of the license.

Operating Loss of $149,180 recognized during the year ended June 30, 2023 was approximately 164% higher than the Operating Loss recognized during the same period ended 2022 which was $56,373. The increase in Operating Loss is primarily attributable to substantially higher Research and Development and Consulting expenses incurred during the period ended 2023 as compared to the same period ended 2022.

Net Loss for the year ended June 30, 2023 was $180,304 which is approximately 26% lower than the Net Loss recognized by the Company during the same period ended 2022. This decrease is primarily attributable to the recognition of $175,721 of Unrealized Loss on Investment Securities during the period ended 2022 .

As of June 30, 2023 we had $3,786 in cash on hand and current liabilities of $241,411 such liabilities consisting of Income Tax Payable, Notes Payable, and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

Management plans to raise additional funds by obtaining governmental and nongovernmental grants as well as offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings. Management can give no assurance that any governmental or nongovernmental grant will be obtained by the Company despite the Company’s best efforts.

As of June 30, 2023 the Company was not party to any binding agreements which would commit SYBLEU to any material capital expenditures.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

As we are a smaller reporting company, as defined by Rule 229.10(f)(1), we are not required to provide the information required by this Item.

1419

Item 8. Financial Statements and Supplementary Data.

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of SYBLEU INC.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of SYBLEU INC. as of June 30, ~~2022~~2023 and ~~2021~~2022, the related statements of operations, stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, ~~2022~~2023 and ~~2021~~2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matter

Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

We determined that there are no critical audit matters.

/S/ BF Borgers CPA PC (PCAOB ID 5041)

We have served as the Company's auditor since 2020

#5041

Lakewood, CO

~~July~~August 204, ~~2022~~2023

SYBLEU INC.
BALANCE SHEETS
	As of June 30,2022			As of June 30,2021 (as restated)
ASSETS
CURRENT ASSETS
Cash	$	66,850		$	14,297
Prepaid Expenses		0			0
Total Current Assets	$	66,850		$	14,297
OTHER ASSETS
Investment Securities		9,529			185,250
Total Other Assets		9,529			185,250
TOTAL ASSETS	$	76,379		$	199,547
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Income Taxes Payable		10,935			21,394
Notes Payable		140,000			0
Notes Payable, Related Party		0			8,919
Expenses Accrued but Unpaid		452			450
Interest Accrued but Unpaid		13,253			0
Total Current Liabilities		164,640			30,763
Long Term Liabilities:
Unearned Income		161,699			173,398
Total Liabilities	$	326,338		$	204,161
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 100,000,000 shares authorized; par value $0.0001 10,418,000 shares issued and outstanding as of June 30, 2022 and June 30,2021		1,042			1,042
Additional Paid in capital		100,049			100,049
Retained Earnings (Deficit )		(351,051	)		(105,705	)
Total Stockholders' Equity (Deficit)		(249,960	)		(4,614	)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$	76,379		$	199,547

The Accompanying Notes are an Integral Part of These Financial Statements

SYBLEU INC.
STATEMENT OF OPERATIONS
	Year Ended June 30,2022			Year Ended June 30,2021 (as restated)
REVENUES
License Fees		11,700			4,052
TOTAL REVENUES	$	11,700		$	4,052
COSTS AND EXPENSES
Research and Development:
Consulting Costs		0			26,311
Patent Application Costs		5,058			3,100
Total Research and Development		5,058			29,411
General and Administrative:
Transfer Agency Fees		1,884			6,115
Other General and Administrative Expenses		13,731			1,898
Total General and Administrative		15,616			8,013
Consulting:
Legal Fees		0			500
Accounting		47,400			11,880
Other Consulting		0			13,600
Information Technology Consulting		0			23,900
Total Consulting		47,400			49,880
Rent					5,000
Total Costs and Expenses		68,073			92,304
OPERATING Income(LOSS)	$	(56,374	)	$	(88,252	)
OTHER INCOME AND EXPENSES
Unrealized Gain (Loss) on Investment Securities		(175,721	)		7,800
Interest Income(Expense)		(13,252	)		0
TOTAL OTHER INCOME (EXPENSES)		(188,973	)		7,800
NET INCOME (LOSS) Before Taxes		(245,347	)		(80,452	)
Provision for Income Taxes		0			(21,394	)
NET INCOME (LOSS)	$	(245,347	)	$	(101,846	)
BASIC AND FULLY DILUTED
LOSS PER SHARE	$	(0.02	)	$	(0.01	)
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING		10,418,000			10,054,932

The Accompanying Notes are an Integral Part of These Financial Statements

SYBLEU INC.
STATEMENT OF SHAREHOLDERS EQUITY (DEFICIT)
For the Year Ended June 30, 2022
	Common
	Shares		Amount		Additional Paid in Capital		Retained Deficit			Total
Balance June 30, 2021		10,418,000	$	1,042	$	100,049	$	(105,705	)	$(4,614)
Net Loss for the three months ended September 30,2021		-		-		-		(132,307	)	$(132,307)
Balance September 30,2021		10,418,000	$	1,042	$	100,049	$	(238,012	)	$(136,921)
Net Loss for the three months ended December 31,2021		-		-		-	$	(61,751	)	$(61,751)
Balance December 31, 2021		10,418,000	$	1,042	$	100,049	$	(299,763	)	$(198,672)
Net Loss for the three months ended March 31, 2022		-		-		-	$	(27,030	)	$(27,030)
Balance March 31, 2022		10,418,000	$	1,042	$	100,049	$	(326,793	)	$(225,702)
Net Loss for the three months ended June 30,2022		-		-		-	$	(24,258	)	$(24,258)
Balance June 30,2022		10,418,000	$	1,042	$	100,049	$	(351,051	)	$(249,960)

The Accompanying Notes are an Integral Part of These Financial Statements

SYBLEU INC.
STATEMENT OF SHAREHOLDERS DEFICIT
For the Year Ended June 30, 2021
(as restated)
	Common
	Shares		Amount		Additional Paid in Capital		Retained Deficit			Total
Balance June 30, 2020		9,353,000	$	935	$	145	$	(3,859	)	$(2,779)
Common shares issued for nonemployee services July 8,2020		65,000		7		4				11
Net Loss Quarter ended September 30,2020		-		-		-		(21,896	)	(21,896)
Balance September 30,2020		9,418,000	$	942	$	149	$	(25,755	)	$(24,664)
Common Stock issued for cash November 9 2020		1,000,000	$	100	$	99,900				$100,000
Net Loss Quarter ended December 31,2020		-		-		-	$	(34,463	)	$(34,463)
Balance December 31, 2020		10,418,000	$	1,042	$	100,049	($	60,218	)	$40,873
Net Loss Quarter Ended March 31, 2021		-		-		-	($	86,599	)	($86,599)
Balance March 31, 2021		10,418,000	$	1,042	$	100,049	$	(146,817	)	$(45,726)
Net Income Quarter Ended June 30, 2021		-		-		-		41,112		41,112
Balance June 30, 2021		10,418,000	$	1,042	$	100,049	$	(105,705	)	$(4,614)

The Accompanying Notes are an Integral Part of These Financial Statements

SYBLEU INC.
STATEMENT OF CASH FLOWS
	Year Ended June 30, 2022			Year Ended June 30, 202 (as restated)
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$	(245,347	)	$	(101,846	)
Adjustments to reconcile net Income (loss) to net cash
Common Stock Issued for payment of expenses		—			11
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses		—			3,500
Increase (Decrease) in Accrued Expenses		13,257			450
(Increase) Decrease in Securities accepted as Payment		—			(177,450	)
Increase(Decrease) in Unearned Income		(11,700	)		173,398
Increase (Decrease) in Income Tax Payable		(10,459	)		21,394
Unrealized Loss ( Gain) in Investment Securities		175,721			(7,800	)
Net Cash provided by (used) in Operating Activities	$	(78,528	)	$	(88,343	)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in Notes Payable, Related Parties		(8,919	)		(2,410	)
Increase (Decrease) in Notes Payable		140,000
Common Stock issued for Cash		—			100000
Net Cash provided by (used) in Financing Activities		131,081			97,590
Net Increase (Decrease) in Cash		52,553			9,247
Cash at Beginning of Period		14,297			5,050
Cash at End of Period	$	66,850		$	14,297
Supplemental Cash Flow Information:
Interest Paid	$	—		$	—
Income Taxes Paid	$	10,459		$	—

The Accompanying Notes are an Integral Part of These Financial Statements


SYBLEU INC.
BALANCE SHEETS

	As of June 30, 2023			As of June 30, 2022
ASSETS
CURRENT ASSETS
Cash	$	3,786		$	66,850
Prepaid Expenses		15,613			0
Total Current Assets	$	19,399		$	66,850
OTHER ASSETS
Investment Securities		1,920			9,529
Prepaid Expenses (Long Term)		9,149
Acquired Intangible Assets, net of amortization		300,000
Total Other Assets		311,069			9,529
TOTAL ASSETS	$	330,468		$	76,379

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Income Taxes Payable		10,935			10,935
Notes Payable		177,500			140,000
Notes Payable, Related Party					0
Expenses Accrued but Unpaid		15,500			452
Interest Accrued but Unpaid		27,476			13,253
Total Current Liabilities		231,411			164,640
Long Term Liabilities:
Unearned Income		150,002			161,699
Note Payable		300,000
Total Liabilities	$	681,413		$	326,338

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 100,000,000 shares authorized; par value $0.0001; 10,418,000 shares issued and outstanding as of June 30, 2022 and 10,613,492 shares issued and outstanding as of June 30, 2023		1,062			1,042
Additional Paid in capital		179,348			100,049
Retained Earnings (Deficit )		(531,355	)		(351,051	)
Total Stockholders' Equity (Deficit)		(350,945	)		(249,960	)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$	330,468		$	76,379

The Accompanying Notes are an Integral Part of These Financial Statements


SYBLEU INC.
STATEMENT OF OPERATIONS

	Year Ended June 30, 2023			Year Ended June 30, 2022
REVENUES
License Fees		11,696			11,700
TOTAL REVENUES	$	11,696		$	11,700
COSTS AND EXPENSES
Research and Development:
Staff Expenses		2,212			—
Consulting Costs		—			—
Licensing Expenses		82,275			—
Patent Application Costs		1,002			5,058
Total Research and Development		85,489			5,058
General and Administrative:
Transfer Agency Fees		2,807			1,884
Other General and Administrative Exexpenses		14,105			13,731
Total General and Administrative		16,912			15,615
Consulting, Related Party		4,716			—
Consulting:
Legal Fees		—			—
Accounting		27,500			47,400
Other Consulting
Website Development		3,000			—
Information Technology Consulting		10,759			—
Securities Depository Consulting		12,500			—
Total Consulting		58,475			47,400
Rent		—			—
Total Costs and Expenses		160,876			68,073

OPERATING Income( LOSS)	$	(149,180	)	$	(56,373	)

OTHER INCOME AND EXPENSES
Unrealized Gain ( Loss) on Investment Securities		(7,609	)		(175,721	)
Stock Cancellation Expense		(9,294	)		—
Interest Income( Expense)		(14,221	)		(13,252	)
TOTAL OTHER INCOME ( EXPENSES)		(31,124	)		(188,973	)

NET INCOME ( LOSS) before taxes		(180,304	)		(245,347	)
Provision for Income Taxes
NET INCOME ( LOSS)	$	(180,304	)	$	(245,347	)
BASIC AND FULLY DILUTED LOSS PER SHARE	$	(0.02	)	$	(0.02	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		10,328,955			10,418,000

The Accompanying Notes are an Integral Part of These Financial Statements


SYBLEU INC.
STATEMENTS OF SHAREHOLDERS EQUITY (DEFICIT)

For the Year Ended June 30, 2023
	Common
	Shares			Amount			Additional Paid in Capital			Retained Deficit			Total
Balance June 30, 2022		10,418,000		$	1,042		$	100,049		$	(351,051	)	$	(249,960	)
Net Loss for the quarter ended September 30, 2022											(19,750	)		(19,750	)
Balance September 30, 2022		10,418,000		$	1,042		$	100,049		$	(370,801	)	$	(269,710	)
Cancellation of shares 12/13/2022		(6,113,508	)	$	(611	)	$	(95	)				$	(706	)
Issuance of shares for services 12/12/2022		6,000,000		$	600		$	22,260					$	22,860
Net Loss for the quarter ended December 31, 2022										$	(18,527	)	$	(18,527	)
Balance December 31, 2022		10,304,492		$	1,031		$	122,214		$	(389,328	)	$	(266,083	)
Net Loss for the quarter ended March 31, 2023										$	(29,034	)	$	(29,034	)
Balance March 31, 2023		10,304,492		$	1,031		$	122,214		$	(418,362	)	$	(295,117	)
Issuance of shares as consideration 06/28/2023		309,000		$	31		$	57,134					$	57,165
Net Loss for quarter ended June 30, 2023										$	(112,993	)	$	(112,993	)
Balance June 30, 2023		10,613,492		$	1,062		$	179,348		$	(531,355	)	$	(350,945	)

For the Year Ended June 30, 2022
		Common
		Shares			Amount			Additional Paid in Capital			Retained Deficit			Total
Balance June 30, 2021		10,418,000		$	1,042		$	100,049		$	(105,705	)	$	(4,614	)
Net Loss for the three months ended September 30,2021											(132,307	)	$	(132,307	)
Balance September 30, 2021		10,418,000		$	1,042		$	100,049		$	(238,012	)	$	(136,921	)
Net Loss for the three months ended December 31,2021										$	(61,751	)	$	(61,751	)
Balance December 31, 2021		10,418,000		$	1,042		$	100,049		$	(299,763	)	$	(198,672	)
Net Loss for the three months ended March 31, 2022										$	(27,030	)	$	(27,030	)
Balance March 31, 2022		10,418,000		$	1,042		$	100,049		$	(326,793	)	$	(225,702	)
Net Loss for the three months ended June 30, 2022										$	(24,548	)	$	(24,548	)
Balance June 30, 2022		10,418,000		$	1,042		$	100,049		$	(351,051	)	$	(249,960	)

The Accompanying Notes are an Integral Part of These Financial Statements


SYBLEU INC.
STATEMENT OF CASH FLOWS

	Year Ended June 30, 2023			Year ended June 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$	(180,304	)	$	(245,347	)
Adjustments to reconcile net Income (loss) to net cash
Common Stock Issued for payment of expenses		65,546
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses		(10,283	)
Increase (Decrease) in Accrued Expenses		29,270			13,257
(Increase) Decrease in Securities accepted as Payment
Increase( Decrease) in Unearned Income		(11,696	)		(11,700	)
Increase ( Decrease) in Income Tax Payable					(10,459	)
Decrease in Common Stock		(611	)
Decrease in Additional Paid in Capital		(95	)
Unrealized Loss (Gain) in Investment Securities		7,609			175,721
Net Cash provided by (used) in Operating Activities	$	(100,564	)	$	(78,528	)

CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in Notes Payable, Related Parties					(8,919	)
Increase (Decrease) in Notes Payable		37,500			140,000
Common Stock issued for Cash
Net Cash provided by (used) in Financing Activities		37,500			131,081

Net Increase (Decrease) in Cash	$	(63,064	)	$	52,553
Cash at Beginning of Period		66,850			14,297
Cash at End of Period	$	3,786		$	66,850

Supplemental Cash Flow Information:
Interest Paid	$	—		$	—
Income Taxes Paid	$	—		$	10,459

The Accompanying Notes are an Integral Part of These Financial Statements

SYBLEU INC.

Notes to Condensed Financial Statements

As of June 30, ~~2022~~2023

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SYBLEU INC. (“Company”) was organized June 12, 2020 under the laws of the State of Wyoming.

The Company intends to engage primarily in the acquisition, licensing and development of regenerative medical applications up to the point of successful completion of Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials.

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end.

B. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

D. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

E. RESEARCH AND DEVELOPMENT COSTS

Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application.

F. STOCK BASED COMPENSATION

Stock issued for Employee Compensation

Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient.

During the ~~year~~quarter ended ~~June~~December 3031, 2022 ~~no stock~~ ~~was~~6,000,000 shares of common stock were issued ~~for~~as employee compensation.

In determining Fair Value for shares issued to employees an asset based valuation method was utilized , specifically Enterprise Value (Assets Less Cash and Cash Equivalents plus Fair Value of Debt) less Fair Value of Debt. The following inputs were utilized.


Fair Value of Intellectual Property	$	35,490
Securities	$	3,771
Notes Payable	$	140,000
Accrued Interest	$	19,504
Taxes Payable	$	10,935
Less Total Debt	$	(170,439	)
Portion of Enterprise Value available to shareholders	$	39,261
Fair Value per share	$	0.00381

Stock issued for Non-Employee Services

Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable

During the year ended June 30, ~~2022~~ 2023 no stock was issued for Non-Employee Services .

Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:

The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and

ii.

The date at which the counterparty’s performance is complete.

G. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides ~~clarification~~ clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, ~~2022~~2023 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

H. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of June 30, ~~2022~~2023.

I. INTANGIBLE ASSETS

The Company amortizes its intangible assets with definite useful lives over their estimated useful lives and reviews these assets for impairment. The Company’s acquired intangible assets with definite useful lives consists of a 50% interest in and to including, but not limited to, the copyrights, trade secrets, trademarks and associated good will and patent rights to (a) the intellectual property disclosed in US Patent US11377442B2 (Small molecule agonists and antagonists of NR2F6 activity) and (b) ) the intellectual property disclosed in US Patent US US10472351B2 (Small molecule agonists and antagonists of NR2F6 activity in animals).

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

The Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification.

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company has adopted the provisions of this ASU effective the fiscal year ended 2020. This guidance did not have a material impact on the Company’s Financial Statements.

On February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842). The ASU requires organizations that lease assets, referred to as "lessees," to recognize on the consolidated statement of financial position the rights and obligations created by those leases. The ASU also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the consolidated financial statements. The ASU on leases became effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. This guidance is not expected to have a material impact on the Company’s financial statements.

In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. This ASU is effective for annual periods beginning after December 15, 2018 and interim periods within those annual periods, with early adoption permitted. This guidance is not expected to have a material impact on the Company’s financial statements.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has ~~generated~~ generated net losses of $~~351~~531,~~051~~355 during the period from June 12, 2020 (inception) through June 30,~~2022~~ 2023. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.

NOTE 4. RELATED PARTY TRANSACTIONS.

The Company utilizes approximately ~~2,300~~500 square feet of office space at ~~4700~~1034 ~~Spring~~Throggs ~~Street,~~Neck ~~Suite 304~~Expressway, LaBronx ~~Mesa~~NY ~~California,~~10465 ~~91941~~ provided to the Company by ~~BST~~Joseph ~~Partners~~G. Vaini, ~~Inc.~~the Company’s sole officer and director, on a month to month basis free of charge. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space. ~~BST Partners, Inc. is a company controlled by SYBLEU’s Chairman and CEO.~~

On January 8, 2023 the Company entered into an agreement with Joanne Vaini whereby Joanne Vaini agreed to provide bookkeeping services for the Company for the period beginning January 9, 2023 and ending July 9, 2024 (“Agreement”) for total consideration consisting of $15,000. Joanne Vaini is the spouse of Joseph G. Vaini the Company’s sole officer and director.

On June 26, 2023 the Company was granted an exclusive worldwide license by DYO Biotechnologies, Pty, Ltd (“DYO”) to (a) to make, have made, use, offer for sale, sell, perform, have performed export and import Licensed Products and Licensed Services; (b) to practice Licensed Methods; and (c) to use Technology, all in the Field, within the Territory and during the Term (the “License”).

“Technology” is defined in the License as” Artificial intelligence/machine learning engine designed to utilize existing chemical library structures in an integrated model to predict highly specific and sensitive novel chemical structures for molecular targets.”

“Licensed Products” are defined in the License as “any product, kit, composition, or part thereof: (a) that incorporates, uses, or is enabled or derived from the use of the Technology; or (b) that is produced or enabled by a Licensed Method.”

“Licensed Method” is defined in the License as “any method or process that uses Technology”

“Field” is defined in the License as small molecule drug development and commercialization for human and/or animal health.

“Territory” is defined in the License as “worldwide”.

The Term of the License is the period of time beginning on the effective date of this Agreement which shall be June 26, 2023 and terminating on the last to expire Royalty Term .

Pursuant to the terms and conditions of the License the l Company paid to DYO 309,000 common shares of the Company (“Stock Payment”) and also paid a $25,000 License Issuance Fee.

Milestone	AMOUNT
1. Dosing of a first human patient in a Phase I or Phase I/II Clinical Trial for Licensed Product	$150,000 US
2. Dosing of a first patient in a Phase III Clinical Trial for Licensed Product	$500,000 US
3. FDA (US) Approval of a Licensed Product	$3,000,000 US
4. EMA (EU) Approval of a Licensed Product	$1,500,000 US
5. PMDA (JPN) Approval of a Licensed Product	$1,000,000 US
6. Cumulative Net Sales of Licensed Products reach $100 Million	$2,000,000 US

This License may be terminated by DYO in the event:

No licensed Method, Service or Product has been granted Patent Protection in at least one jurisdiction after the expiration of four years from execution

The sum of $2,000,000 shall not have been raised within 2 years of execution of the license

The Research Agreement shall not have been entered into as of thirty days subsequent to the Funding.

The Company shall not have achieved cumulative Net Sales of Licensed Product, Service and Methods of at least $10,000,000 as of a date that is ten years from the execution of the license

The Company shall fail to pay any consideration required under the license and such failure remains uncured for thirty days.

This License may be terminated by the Company in the event:

DYO shall be determined to not have exclusive unencumbered Patent Rights to the Technology in whole or in part.

DYO shall have failed to demonstrate during the course of due diligence to the satisfaction of the Company that the Technology can be effectively utilized for the purposes intended by this License

In the event that the Agreement is terminated pursuant to the any of the abovementioned the Stock Payment shall be promptly returned by DYO to the Company for cancellation.

On July 14, 2023 the Company’s Chief Executive Officer made a $3,600 capital contribution to the Company.

NOTE 5. NOTES PAYABLE

Schedule of related party debt
Bostonia Partners	$	140,000
Notes Payable, as of June 30, 2022	$	140,000
Zander Therapeutics Inc.	$	12,500
Zander Biologics, Inc.	$	300,000
Notes Payable, as of June 30, 2023	$	477,500

$10,000 owed by the Company to Bostonia Partners bears simple interest at %10% and is due and payable September 20, 2022.

$30,000 owed by the Company to Bostonia Partners bears simple interest at %10% and is due and payable September 30, 2022.

$100,000 owed by the Company to Bostonia Partners bears simple interest at %10% and is due and payable October 5, 2022.

$12,500 owed by the Company to Zander Therapeutics, Inc bears simple interest at 10% and is due and payable April 4, 2024.

$25,000 owed by the Company to Bostonia Partners bears simple interest at 10% and is due and payable June 29, 2024.

$300,000 owed by the Company to Zander Biologics, Inc bears simple interest at 10% and is due and payable June 30, 2025.

NOTE 6. INVESTMENT SECURITIES

On March 11, 2021 the Company was paid 6,500 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between the Company and Oncology Pharma, Inc. whereby the Company granted Oncology Pharma, Inc. an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company.

On June 30, ~~2022~~2023 the Company revalued 6,500 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market.

As of June 30, ~~2022~~2023:

Schedule Of Common Shares

6,500 Common Shares of Oncology Pharma, Inc.

~~Basis~~

Basis

~~Fair Value~~

Fair Value

~~Total Unrealized Losses~~

Total Unrealized Losses

~~Net Unrealized Gain or (Loss) realized during the Quarter ended June 30,2022~~

Net Unrealized Gain or (Loss) during the quarter ended June 30, 2023

177,450

91,~~529~~920

(~~167~~175,~~921~~530

)

(~~14,521~~718

)

NOTE 87. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following class of capital stock as of June 30, ~~2022~~2023:

Common stock, $ 0.0001 par value; 100,000,000 shares authorized: 10,~~418~~613,~~000~~ 492 shares issued and outstanding.

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

24NOTE 8. INCOME TAXES

~~NOTE~~As 9.of ~~INCOME~~June ~~TAXES~~30, 2023

As of June 30, 2022

Deferred tax assets:
Net operating tax carry forwards	$	97,076
Other		0
Gross deferred tax assets		97,076
Valuation allowance		(97,076	)
Net deferred tax assets	$	0

Schedule of Deferred Tax Assets
Deferred tax assets:
Net operating tax carry forwards	$	80,876
Other		0
Gross deferred tax assets		80,876
Valuation allowance		(80,876	)
Net deferred tax assets	$	0

As of June 30, 2023 the Company has a Deferred Tax Asset of $97,076 completely attributable to net operating loss carry forwards of approximately $60,219 generated during the calendar year ending December 31, 2020 and 98,368 generated during the calendar year ended December 31, 2021 and $77,144 generated during the calendar year ended December 31, 2022 (which expire 20 years from the date the loss was incurred).

As of June 30, 2022 the Company has a Deferred Tax Asset of $80,876 completely attributable to net operating loss carry forwards of approximately $60,219 generated during the calendar year ending December 31,2020 and 98368 generated during the calendar year ended December 31,2021 (which expire 20 years from the date the loss was incurred).

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain.

In addition, if as a result of a stock transfer or a reorganization, a corporation undergoes an “ownership change,” Code Section 382 limits the corporation’s right to use its NOLs each year thereafter to an annual percentage of the fair market value of the corporation at the time of the ownership change (the “Section 382 Limitation”).

A corporation is considered to undergo “an ownership change” if, as a result of changes in the stock ownership by “5-percent shareholders” or as a result of certain reorganizations, the percentage of the corporation’s stock owned by those 5-percent shareholders increases by more than 50 percentage points over the lowest percentage of stock owned by those shareholders at any time during the prior three-year testing period. Five-percent shareholders are persons who hold 5% or more of the stock of a corporation at any time during the testing period as well as certain groups of shareholders (based typically on whether they acquired their shares in a single offering or exchange transaction) who are not individually 5-percent shareholders.

As the Company will require cash infusions in order to implement its business plan, and as it is probable, although not guaranteed, that such funding needs may be met through the sale of equity securities to “5-percent shareholders”, the Company recognized a valuation allowance equal to the deferred Tax Asset and the Company recorded a valuation allowance reducing all deferred tax assets to 0.

Income tax is calculated at the 21% Federal Corporate Rate.

2531

NOTE 109. ~~RESTATEMENT~~STOCK ~~OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS~~TRANSACTIONS

~~Subsequent~~On toDecember 12, 2022 the ~~original~~Company ~~issuance~~issued of3,000,000 ~~the~~common ~~Company’s~~shares ~~quarterly~~(“Shares”) ~~financial~~to ~~statements~~Joseph ~~for~~G ~~the~~Vaini ~~year~~pursuant ~~ended~~to ~~June~~an 30agreement whereby Joseph G. Vaini agreed to serve as President, ~~2021~~Chief ~~the~~Executive ~~Company~~Officer, ~~determined~~Secretary, Chief Financial Officer and Secretary, Treasurer and ~~that~~Principal ~~the~~Accounting ~~following~~Officer ~~revisions~~of ~~are~~the ~~required~~Company.

~~Recognizing~~On ~~revenue~~December of12, ~~$177~~2022 the Company issued 3,~~450 resulting~~000,000 ~~from~~common ~~licensing~~shares ~~fees~~(“Shares”) ~~paid~~to ~~during~~Harry ~~the~~Lander ~~quarter~~pursuant ~~ended~~to ~~March~~an ~~31,2021~~agreement ~~over~~whereby Harry ~~the~~Lander ~~term~~agreed to serve as Chief Scientific Officer of the ~~license ( 15 years)~~Company.

~~Cumulative~~On ~~Effect~~December 13, 2022 the Company cancelled 6,113,508 common shares owned by David Koos, the Company’s previous sole officer and director, and a company controlled by David Koos. Effective December 13, 2022 David Koos resigned as a Director of ~~Restatement~~the Company and also resigned from any and all other offices he had held of ~~Previously~~the ~~Issued~~Company ~~Financial~~(“Resignation”). ~~Statements~~In connection with his Resignation Koos has returned any and all common shares directly or indirectly held by Koos to the Company for cancellation. Also in connection with his Resignation Koos and the ~~Year~~Company ~~Ended~~have ~~Ended~~entered ~~June~~into 30an ~~2021~~agreement ( “Separation Agreement”) whereby the Company shall pay Koos the sum of $10,000.

Schedule of restatement of previously issued Financial Statements
Year Ended June 30, 2021
	Balance Sheet
		As Originally Presented	Adjustments		As Restated
Unearned Income		0	173,398		173,398
Total Liabilities:		30,763	173,398		204,161
Retained Earnings (Deficit )		67,693	(173,398	)	(105,705	)
Total Stockholders' Equity (Deficit)		168,784	(173,398	)	(4,614	)
Year Ended June 30, 2021
		Statement of Operations
		As Originally Presented	Adjustments		As Restated
License Fees		177,450	(173,398	)	4,052
Total Revenue		177,450	(173,398	)	4,052
Operating Income ( Loss)		85,146	(173,398	)	(88,252	)
Net Income (Loss )Before Taxes		92,946	(173,398	)	(80,452	)
Net Income (Loss )		71,552	(173,398	)	(101,846	)
Year Ended June 30, 2021
		Statement of Shareholders' Equity ( Deficit)
		As Originally Presented	Adjustments		As Restated
Net Income ( Loss) Quarter ended March 31, 2021		89,716	—		89,716
Retained Deficit March 31, 2021		29,498	(176,315	)	(146,817	)
Total Stockholders' Equity (Deficit) March 31, 2021		130,589	(176,315	)	(45,726	)
Net Income ( Loss) Quarter ended June 30, 2021		38,195	(173,398	)	(135,203	)
Retained Deficit June 30, 2021		67,693	(173,398	)	(105,705	)
Total Stockholders' Equity (Deficit) June 30, 2021		168,784	(173,398	)	(4,614	)
Year Ended June 30, 2021
		Statement of Cash Flows
		As Originally Presented	Adjustments		As Restated
Net Income (Loss)		38,195	(173,398	)	(135,203	)
Increase ( Decrease) in Unearned Income		0	173,398		173,398

On June 28, 2023 the Company issued 309,000 common shares (“Shares”) to DYO Biotechnologies, Pty, Ltd pursuant to the terms and conditions of an agreement entered into by and between DYO Biotechnologies, Pty, Ltd and the Company.

26NOTE 10. SUBSEQUENT EVENTS

On July 14, 2023 the Company’s Chief Executive Officer made a $3,600 capital contribution to the Company.

Item 9A. Controls and Procedures

a) Evaluation of disclosure controls and procedures.

The principal executive officer and principal financial officer have evaluated the Company’s disclosure controls and procedures as of June 30, ~~2022~~2023. Based on this evaluation, they have concluded that the disclosure controls and procedures were effective to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms and to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

b) Management’s annual report on internal control over financial reporting.

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) promulgated under the Securities and Exchange Act of 1934. Rule 13a-15(f) defines internal control over financial reporting as follows:

“The term internal control over financial reporting is defined as a process designed by, or under the supervision of, the issuer's principal executive and principal financial officers, or persons performing similar functions, and effected by the issuer's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer;

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and directors of the issuer; and

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer's assets that could have a material effect on the financial statements.”

The Company’s internal control over financial reporting is a process designed under the supervision of the Company’s management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

In designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only a reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.

The Company’s management assessed the effectiveness of its internal control over financial reporting as of June 30, ~~2021~~2023 is based on the framework in 2013 Committee of Sponsoring Organizations of the Treadway Commission, or COSO. Based on its assessment, management believes that, as of June 30, ~~2021~~2023 the Company’s internal control over financial reporting is effective.

Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the company to provide only management's report in this annual report. This exemption for smaller reporting companies provided under the temporary rules referenced above has been made permanent under Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

(c) There have been no changes during the quarter ended June 30, 2022 in the Company’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.33

27(c) There have been no changes during the quarter ended June 30, 2023 in the Company’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Item 10. Directors, Executive Officers and Corporate Governance

David R. Koos

David R. Koos, 62 has served as Chairman of the Board of Directors, Chief Executive Officer, President, Secretary and Treasurer from inception to the date of this document. David R. Koos served as Chief Financial Officer since inception to July 21, 2020

Position:	Company Name:	Employment Dates:
Chairman, President, Chief Executive Officer, Secretary, Acting Chief Financial Officer, Principal Accounting Officer	Entest Group, Inc.	June 19, 2009 to November 28, 2018
Chairman, President, Chief Executive Officer, Secretary, Chief Financial Officer, Principal Accounting Officer	Entest BioMedical, Inc.( a California corporation)	August 22,2008 to the Present
Chairman and CEO	Regen BioPharma, Inc.	April 24, 2012 to January 22,2020 and again March 23,2021 to the present.
Acting CFO	Regen BioPharma, Inc.	April 24, 2012 to February 11, 2015 and again March 23,2021 to the present.
President	Regen BioPharma, Inc.	May 29, 2013 to October 9, 2013 and again March 23,2021 to the present.
Chairman, CEO	Zander Therapeutics, Inc.	February 2017 to January 22,2020 and again March 23,2021 to the present.
Sole Officer and Director	Cell Source Research, Inc.	March 24, 2003 to the Present
Chairman, President, CEO and Acting CFO	Bio-Matrix Scientific Group, Inc.	June 14, 2006 (Chairman) to July 31;2019 June 19, 2006 (President, CEO and Acting CFO); June 19, 2006 (Secretary) to July 31, 2019
Chairman & CEO	BST Partners Inc. (A California Corporation)	November 30, 2018 to the Present
Chairman & CEO	BST Partners Inc. (A Wyoming Corporation)	March 17, to 2017 to the Present
Chairman and Sole Officer	Regen Biopharma, Inc.	March 23,2021 to the Present
Chairman and Sole Officer	KCL Therapeutics, Inc.	March 23,2021 to the Present
Chairman and Sole Officer	Zander Therapeutics, Inc.	March 23,2021 to the Present

Joseph G. Vaini

Joseph G. Vaini, 5961, has served as Chief Financial Officer since July21, 2020 and as Chairman and sole Director of the Company since December 13, 2022. Mr. Vaini was appointed Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer and Chief Accounting Officer effective December 13, 2022. For the past ten years Mr. Vaini has been a freelance independent consultant assisting microcap companies in complying with securities laws and regulation as well as assisting companies in the preparation of GAAP compliant financial statements. Over the past five years Mr. Vaini has provided consulting services to Bio- Matrix Scientific Group, Inc., Regen BioPharma, Inc., Entest Group, Inc., and Zander Therapeutics, Inc. Mr. Vaini does not possess a college degree. Mr. Vaini worked as a registered securities representative holding a Series 7 and Series 63 License between 1989 and 1995

Harry Lander

On December 9, 2022 Harry Lander, Ph.D., M.B.A was appointed Chief Scientific Officer of SYBLEU INC. effective December 9,2022.

Harry Lander, 57, previously served in the following positions:

Organization:	Title:	Dates:	Primary Business
Dyo Biotechnologies	Managing Director	January 2019 to the Present	Drug Manufacturing and Laboratory Testing
Free Solo Therapeutics, Inc.	Chief Executive Officer, Director	May 2021 to the present	Vascular biology organ regeneration company
Capo Therapeutics, Inc.	Chief Executive Officer, Director	May 2019 to May 2022	Neurodegenerative disease vaccine company
Regen BioPharma, Inc.	President and Chief Scientific Officer	October 2015 to January 2019	Cancer Therapies
Zander Therapeutics, Inc.	President and Chief Scientific Officer	October 2017 to January 2019	Veterinary Therapies

Education:

M.B.A., Finance, 2001

The Stern School of Business, New York, University, New York, NY

Ph.D., Biochemistry, 1992

Cornell University Graduate School of Medical Sciences, New York, NY

B.S., Biochemistry and B.A., Chemistry, 1987

State University of New York at Stony Brook, Stony Brook, NY

Employment Agreements

~~Neither~~On ofDecember ~~David~~9, ~~Koos~~2022 oran agreement (“Agreement”) was entered into by and between the Company and Joseph G. Vaini ~~are~~(“Vaini”) whereby ~~party~~Vaini has agreed to anserve ~~employment~~as ~~agreement~~President, ~~with~~Chief ~~the~~Executive ~~Company~~Officer, Secretary, Chief Financial Officer and ~~serve~~Secretary, atTreasurer and Principal Accounting Officer of the ~~pleasure~~Company subject to the authority of the Company's Board of Directors (the “BOD”). Vaini shall perform such duties commensurate with his offices and as directed the BOD.

The Term of this Agreement shall commence on December 13, 2022 and shall expire on December 13, 2023 unless sooner terminated in accordance with specified provisions contained therein.

As sole compensation for performing his duties pursuant to the Agreement Vaini shall receive 3,000,000 of the Common Shares of the Company ( “Vaini Stock Payment”).Vaini has agreed that for a period of three years from December 9, 2022 Vaini shall not directly or indirectly, offer, issue, sell, contract to sell (including, without limitation, any short sale), grant any option for the sale of, pledge, or otherwise dispose of or transfer the Vaini stock payment.

On December 9, 2022 an agreement (“Agreement”) was entered into by and between the Company and Harry Lander (“Lander”) whereby Lander has agreed to serve as Chief Scientific Officer of the Company subject to the authority of the Company's Board of Directors (the “BOD”). Lander’s duties will include:

Identifying and introducing to the Company Contract Research Organizations

Identifying and introducing to the Company potential strategic partners

Identifying and introducing to the Company potential members for the Company’s Scientific Advisory Board

Assisting the Company in patent application and prosecution.

The Term of this Agreement shall commence on December 9, 2022 and shall expire on December 8, 2025 unless sooner terminated in accordance with specified provisions contained therein.

As sole compensation for performing his duties pursuant to the Agreement Lander shall receive 3,000,000 of the Common Shares of the Company (“Lander Stock Payment”).Lander has agreed that for a period of three years from December 9, 2022 Lander shall not directly or indirectly, offer, issue, sell, contract to sell (including, without limitation, any short sale), grant any option for the sale of, pledge, or otherwise dispose of or transfer the Lander stock payment.

Code of Ethics

On July 20, 2020 we adopted a Code of Ethics pursuant to Section 406 of the Sarbanes-Oxley Act of 2002.

Director Independence

Audit Committee and Audit Committee Financial Expert

The members of the Company’s board of Directors may not be considered independent. The Company is not a "listed company" under Securities and Exchange Commission (“SEC”) rules and is therefore not required to have an audit committee comprised of independent directors. The Company does not currently have an audit committee, however, for certain purposes of the rules and regulations of the SEC and in accordance with the Sarbanes-Oxley Act of 2002, the Company’s Board of Directors is deemed to be its audit committee and as such functions as an audit committee and performs some of the same functions as an audit committee including: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; and (3) engaging outside advisors. The Board of Directors has determined that its member is able to read and understand fundamental financial statements and has substantial business experience that results in that member's financial sophistication. Accordingly, the Board of Directors believes that its member has the sufficient knowledge and experience necessary to fulfill the duties and obligations that an audit committee would have.

Nominating and Compensation Committees

The Company does not have standing nominating or compensation committees, or committees performing similar functions. The board of directors believes that it is not necessary to have a compensation committee at this time because the functions of such committee are adequately performed by the board of directors. The board of directors also is of the view that it is appropriate for the Company not to have a standing nominating committee because the board of directors has performed and will perform adequately the functions of a nominating committee. The Company is not a "listed company" under SEC rules and is therefore not required to have a compensation committee or a nominating committee.

Shareholder Communications

There has not been any defined policy or procedure requirements for stockholders to submit recommendations or nomination for directors. There are no specific, minimum qualifications that the board of directors believes must be met by a candidate recommended by the board of directors. Currently, the entire board of directors decides on nominees, on the recommendation of any member of the board of directors followed by the board’s review of the candidates’ resumes and interview of candidates. Based on the information gathered, the board of directors then makes a decision on whether to recommend the candidates as nominees for director. The Company does not pay any fee to any third party or parties to identify or evaluate or assist in identifying or evaluating potential nominee.

Because the Chief Executive Officer of the Company is also the Chairman of the Board of Directors of the Company, the Board of Directors has determined not to adopt a formal methodology for communications from shareholders on the belief that any communication would be brought to the Board of Directors’ attention by virtue of the co-extensive capacities of the Chairman of the Board of Directors.

Executive Compensation

Name and Principal Position	Fiscal Year		Salary ($)		Bonus ($)		Stock Awards ($)		Restricted Stock Awards ($)		Option Awards ($)		Non Equity Incentive Plan Compensation ($)		Nonqualified Deferred Compensation Earnings ($)		All Other Compensation ($)		Total ($)
David Koos, Chairman, President, CEO, CFO (CFO inception to July 20, 2020)		2021		0		0		0		0		0		0		0		0		0
David Koos, Chairman, President, CEO, CFO (CFO inception to July 20, 2020, Chairman President until December 13, 2022)		2022		0		0		0		0		0		0		0		0		0

Name and Principal Position		Fiscal Year				Salary ($)				Bonus ($)				Stock Awards ($)				Restricted Stock Awards ($)				Option Awards ($)				Non Equity Incentive Plan Compensation ($)				Nonqualified Deferred Compensation Earnings ($)				All Other Compensation ($)				Total ($)
Joseph G. Vaini CFO (since July 21, 2020)			2021				0				0				0				0				0				0				0				0				0

Name and Principal Position		Fiscal Year				Salary ($)				Bonus ($)				Stock Awards ($)				Restricted Stock Awards ($)				Option Awards ($)				Non Equity Incentive Plan Compensation ($)				Nonqualified Deferred Compensation Earnings ($)				All Other Compensation ($)				Total ($)
David Koos, Chairman, President, CEO, CFO (CFO inception to July 20, 2020)			2022				0				0				0				0				0				0				0				0				0

Name and Principal Position		Fiscal Year				Salary ($)				Bonus ($)				Stock Awards ($)				Restricted Stock Awards ($)				Option Awards ($)				Non Equity Incentive Plan Compensation ($)				Nonqualified Deferred Compensation Earnings ($)				All Other Compensation ($)				Total ($)
Joseph G. Vaini CFO (since July 21, 2020)			2022				0				0				0				0				0				0				0				0				0

Employment Agreements

Name and Principal Position		Fiscal Year				Salary ($)				Bonus ($)				Stock Awards ($)				Restricted Stock Awards ($)				Option Awards ($)				Non Equity Incentive Plan Compensation ($)				Nonqualified Deferred Compensation Earnings ($)				All Other Compensation ($)				Total ($)
Joseph G. Vaini CFO (since July 21, 2020) Chairman, President, Treasurer, Chief Executive Officer since December 13, 2022			2023				0				0				0				11,400				0				0				0				0				11.400

Currently the Company is not party to any employment agreement.

Name and Principal Position		Fiscal Year				Salary ($)				Bonus ($)				Stock Awards ($)				Restricted Stock Awards ($)				Option Awards ($)				Non Equity Incentive Plan Compensation ($)				Nonqualified Deferred Compensation Earnings ($)				All Other Compensation ($)				Total ($)
Harry Lander Chief Scientific Officer (since December 9, 2022 )			2022				0				0				0				11,400				0				0				0				0				11,400

2936

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth information known to the Company with respect to the beneficial ownership of each class of the Company’s capital stock for (1) each person known by the Company to beneficially own more than 5% of each class of the Company’s voting securities, (2) each executive officer, (3) each of the Company’s directors and (4) all of the Company’s executive officers and directors as a group.

Based on 10,~~418~~613,~~000~~492 Common Shares outstanding as of July 1631, ~~2022~~2023.

Title of Class	Name and Address of Beneficial ~~Owner~~Holder	Number of ~~shares~~Shares			~~Percentage~~%
Common	~~David~~Harry ~~R. Koos~~Lander		~~6,112,627~~			~~58.67~~	%
	c/o SYBLEU INC
	c/o Sybleu Inc.		3,309,000	(a)		31.18	%
Common	Joseph G Vaini		~~210,790~~			~~2.02~~	%
	c/o SYBLEU INC
	c/o Sybleu Inc.		3,210,790			30.25	%
Common	Stephen Hake*		~~1,040,000~~			~~9.98~~	%
	290 Saddle Run St. Henderson Nv		1,040,000	(b)		9.80	%
Common	~~Timothy~~All Gofficers ~~Foat~~and directors as a group		~~850~~4,349,000	(c)		840.1698	%
	1204 Tangerine Street El Cajon CA
Common	Heather Cassady		800,000			7.68	%
	1391 Broadway St Unit B El Cajon CA
Common	All Officers and Directors as a Group		6,323,417			60.70	%
* Includes 1,000,000 Common Shares held by the The Stephen and Fredna Hake Trust DTD August 6, 2014 for which Dr. Hake serves as a Trustee

(a) Includes 309,000 Common shares held by DYO BIOTECHNOLOGIES PTY LTD.

(b) Includes 1,000,000 Common Shares held by the The Stephen and Fredna Hake Trust DTD August 6, 2014 for which Dr. Hake serves as a Trustee

Item 13. Certain Relationships and Related Transactions, and Director Independence

OnThe ~~June~~Company ~~13,~~utilizes ~~2020~~approximately ~~the~~500 ~~Company~~square ~~issued~~feet 9of office space at 1034 Throggs Neck Expressway,~~353,000~~ ~~common~~Bronx ~~shares~~NY 10465 provided to ~~Cell~~the ~~Source~~Company by ~~Research~~Joseph G. Vaini, the Company’s sole ~~shareholder~~officer and andirector, ~~entity under~~on ~~common~~a ~~control,~~month ~~for~~to ~~consideration~~month ~~consisting~~basis free of ~~payments~~charge. ~~made~~The onproperty ~~behalf~~is ofutilized as office space. We believe that the ~~Company~~foregoing ofproperties ~~$580~~are ~~for~~adequate ~~incorporation~~to ~~expenses~~meet ~~and~~our ~~of $500~~current ofneeds ~~consulting~~for ~~expenses~~office space.

On ~~July~~January 148,~~2020~~ ~~intellectual~~2023 ~~property~~the ~~controlled~~Company byentered into an agreement with Joanne Vaini whereby Joanne Vaini agreed to provide bookkeeping services for the Company’s ~~Chief~~for ~~Executive~~the ~~Officer~~period beginning January 9, 2023 and aending ~~corporation~~July ~~controlled~~9, by2024 ~~the~~(“Agreement”) ~~Company’s~~for total consideration consisting ~~Chief~~of ~~Executive~~$15,000. ~~Officer~~Joanne ~~was~~Vaini ~~assigned~~is tothe spouse of Joseph G. Vaini the Company’s sole officer and director.

30On June 26, 2023 the Company was granted an exclusive worldwide license by DYO Biotechnologies, Pty, Ltd (“DYO”) to (a) to make, have made, use, offer for sale, sell, perform, have performed export and import Licensed Products and Licensed Services; (b) to practice Licensed Methods; and (c) to use Technology, all in the Field, within the Territory and during the Term (the “License”).

On“Technology” ~~December~~is 2,defined ~~2020~~in ~~SYBLEU INC. (~~the ~~“Company~~License as”) ~~was~~Artificial ~~assigned~~intelligence/machine ~~all~~learning ~~right,~~engine ~~title,~~designed ~~and~~to ~~interest~~utilize toexisting ~~intellectual~~chemical ~~property~~library ~~related~~structures toin ~~intratumoral~~an ~~administration~~integrated ofmodel ato ~~combination~~predict ofhighly aspecific ~~chemotherapeutic agent~~ and ansensitive ~~immunomodulatory~~novel ~~agent~~chemical structures for ~~cancer~~molecular ~~therapy ( “Cancer Therapy IP”)~~targets.”

~~These~~ ~~rights~~ “Licensed ~~were~~Products” ~~assigned~~are todefined ~~the~~in ~~Company by~~ the ~~Company’s~~License ~~Chief~~as ~~Executive~~“any ~~Officer~~product, ~~and Entest BioMedical~~kit, ~~Inc.~~composition, aor ~~California~~part ~~corporation controlled~~thereof: ~~by the Company’s Chief Executive Officer. The aforementioned assignment constituted~~ (a) ~~contribution~~that ~~of intellectual property~~incorporates, touses, ~~the~~or ~~Company. There~~ is noenabled ~~termination date of the assignment. No term~~ or ~~condition~~derived offrom the ~~assignment~~use ~~would cause ownership~~ of the ~~intellectual property~~Technology; ~~rights to revert back to David Koos and Entest BioMedical, Inc. No payment of any sort is required by to be made the Company to either David Koos~~ or ~~Entest~~(b) ~~BioMedical,~~that ~~Inc. pursuant to the assignment. The Company~~ is ~~not~~produced ~~required to meet any particular benchmark~~ or ~~pay~~enabled by a ~~royalty~~Licensed ~~of any sort pursuant to this assignment~~Method.”

~~The~~“Licensed ~~Company~~Services” ~~utilizes~~are ~~approximately~~defined ~~2,300~~in ~~square~~the ~~feet~~License ofas ~~office~~“any ~~space~~service atperformed ~~4700~~by ~~Spring~~Company ~~Street,~~or ~~Suite~~Sublicensee ~~304,~~for ~~La Mesa California, 91941 provided to~~ the ~~Company~~benefit byof ~~BST Partners, Inc. on~~ a ~~month~~third toparty that, ~~month~~in ~~basis~~whole ~~free~~or ofin ~~charge. The property is utilized as office space. During the year ended June 30~~part, ~~2021~~(a) ~~the~~uses ~~Company~~Technology; ~~voluntarily~~(b) ~~paid~~uses ~~$5,000~~Licensed inProduct(s); ~~rental~~or ~~expenses~~(c) tothat ~~BST~~practices ~~Partner’s~~or ~~landlord~~is onenabled ~~behalf~~by ofa ~~BST~~Licensed ~~Partners, Inc~~Method.”

“Licensed Method” is defined in the License as “any method or process that uses Technology”

“Field” is defined in the License as small molecule drug development and commercialization for human and/or animal health.

“Territory” is defined in the License as “worldwide”.

The Term of the License is the period of time beginning on the effective date of this Agreement which shall be June 26, 2023 and terminating on the last to expire Royalty Term .

Pursuant to the terms and conditions of the License the Company paid to DYO 309,000 common shares of the Company (“Stock Payment”) and also paid a $25,000 License Issuance Fee.

Milestone	AMOUNT
1. Dosing of a first human patient in a Phase I or Phase I/II Clinical Trial for Licensed Product	$150,000 US
2. Dosing of a first patient in a Phase III Clinical Trial for Licensed Product	$500,000 US
3. FDA (US) Approval of a Licensed Product	$3,000,000 US
4. EMA (EU) Approval of a Licensed Product	$1,500,000 US
5. PMDA (JPN) Approval of a Licensed Product	$1,000,000 US
6. Cumulative Net Sales of Licensed Products reach $100 Million	$2,000,000 US

This License may be terminated by DYO in the event:

No licensed Method, Service or Product has been granted Patent Protection in at least one jurisdiction after the expiration of four years from execution

The sum of $2,000,000 shall not have been raised within 2 years of execution of the license

The Research Agreement shall not have been entered into as of thirty days subsequent to the Funding.

The Company shall not have achieved cumulative Net Sales of Licensed Product, Service and Methods of at least $10,000,000 as of a date that is ten years from the execution of the license

The Company shall fail to pay any consideration required under the license and such failure remains uncured for thirty days.

This License may be terminated by the Company in the event:

DYO shall be determined to not have exclusive unencumbered Patent Rights to the Technology in whole or in part.

DYO shall have failed to demonstrate during the course of due diligence to the satisfaction of the Company that the Technology can be effectively utilized for the purposes intended by this License

In the event that the Agreement is terminated pursuant to the any of the abovementioned the Stock Payment shall be promptly returned by DYO to the Company for cancellation.

On July 14, 2023 the Company’s Chief Executive Officer made a $3,600 capital contribution to the Company.

Item 14. Principal Accounting Fees and Services

The following table sets forth the aggregate fees billed to us by BF Borgers CPA PC for the period beginning July 1,~~2020~~2022 and ending June 30, ~~2021~~2023:

Audit Fees	$	~~3000~~11,000
Audit Related Fees		~~5640~~16,500
Tax Fees		0
All Other Fees		0
Total:	$	827,~~640~~500

The following table sets forth the aggregate fees billed to us by BF Borgers CPA PC for the period beginning July 1,2021 and ending June 30, 2022:

Audit Fees	$	25,800
Audit Related Fees		21,600
Tax Fees		0
All Other Fees		0
Total:	$	47,400

Audit Fees: Aggregate fees billed for professional services rendered for the audit of the Company's annual financial statements.

Audit Related Fees: Aggregate fees billed for professional services rendered for assurance and related services that were reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees” above. These fees were primarily derived from review of financial statements in the Company's Form 10Q Reports.

All services listed were pre-approved by the Board of Directors, functioning as the Audit Committee in accordance with Section 2(a) 3 of the Sarbanes-Oxley Act of 2002.

3140

EXHIBITS

Exhibit	No. Description
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002
31.2	Certification of Chief Financial Officer Pursuant to Section 3026 of the Sarbanes Oxley Act of 2002
32.1	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes Oxley Act of 2002
32.2	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes Oxley Act of 2002
3(i)	Articles of Incorporation
3(ii)	Bylaws
10.1	Agreement with Dr. Stephen Hake
10.2	Agreement with Dr. Jason Garber
10.21	Assignments
10.22	Stock Purchase Agreement
10.33	Assignment dated 12/2
10.38	License Agreement
10.7	Note Payable $20,000
10.8	Note Payable $30,000
10.9	Note Payable $100,000
10.10	Separation Agreement
10.11	Employment Agreement Vaini
10.12	Employment Agreement Lander
10.13	Joanne Vaini Agreement
10.14	License Agreement DYO
10.15	Zander Biologics IP Purchase Agreement
10.16	Note Payable $12,500
10.17	Note Payable $25,000

3241

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		SYBLEU INC.
	By:	/s/ ~~David~~Joseph RG. ~~Koos~~Vaini
	Name:	~~David~~Joseph RG. ~~Koos~~Vaini
	Title:	Chairman, Chief Executive Officer, Director
		Title: Chairman, Chief Executive Officer, Director, Chief Financial Officer, Chief Accounting Officer
	Date:	~~July~~August 224, ~~2022~~2023

		SYBLEU INC.
	By:	/s/ Joseph G. Vaini
	Name:	Joseph G. Vaini
	Title:	Chief Financial Officer
	Date:	July 22, 2022

Filing Compare · SYBLEU Inc